Delaware
(State
or other jurisdiction of
incorporation
or organization)
|
3841
(Primary
Standard Industrial
Classification
Code Number)
|
83-0221517
(I.R.S.
Employer
Identification
No.)
|
||
2600
Stemmons Freeway, Suite 176
Dallas,
Texas 75207
(214)
905-5100
(Address,
Including Zip Code, and Telephone Number, Including Area Code, of
Registrant’s Principal Executive Offices)
|
||||
Stephen
B. Thompson
Chief
Financial Officer
Access
Pharmaceuticals, Inc.
2600
Stemmons Freeway, Suite 176
Dallas,
Texas 75207
(214)
905-5100
(Name,
Address, Including Zip Code, and Telephone Number, Including Area
Code, of
Agent for Service)
|
with
a copy to:
|
John
J. Concannon III, Esq.
Bingham
McCutchen LLP
150
Federal Street
Boston,
MA 02110
(617)
951-8000
|
|
||||||||
Title
of Each Class of
Securities
to be Registered
|
Amount
to
be
Registered
|
Proposed
Maximum
Offering
Price
Per
Security
|
Proposed
Maximum
Aggregate
Offering
Price
|
Amount
of
Registration
Fee
|
||||
|
||||||||
Common
stock, $0.01 par value per share
|
11,666,195
(1)
|
$
2.01(5)
|
$23,449,052
|
$922
(5)
|
||||
Common
stock, $0.01 par value per share
|
4,149,464
(2)
|
$
2.01(5)
|
$8,340,423
|
$328
(5)
|
||||
Common
stock, $0.01 par value per share
|
772,728(
3)
|
$
2.01(5)
|
$1,553,183
|
$61
(5)
|
||||
Common
stock, $0.01 par value per share
|
1,582,360
(4)
|
$
2.01(5)
|
$3,180,544
|
$125
(5)
|
||||
Total
common stock, $0.01 par value per share
|
18,170,747
|
$36,523,202
|
$1,436
|
|||||
|
Page |
|
||
PROSPECTUS SUMMARY | 1 |
|
|
EXPLANATORY
NOTE
|
1 | ||
ABOUT
ACCESS
|
1 | ||
SUMMARY
OF THE
OFFERING
|
5 | ||
SUMMARY
CONDENSED CONSOLIDATED FINANCIAL INFORMATION
|
6 | ||
RISK FACTORS | 10 | ||
FORWARD-LOOKING STATEMENTS | 19 | ||
SELLING STOCKHOLDERS | 20 | ||
USE OF PROCEEDS | 25 | ||
PLAN OF DISTRIBUTION | 25 | ||
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
|
27 | ||
DESCRIPTION OF BUSINESS | 39 | ||
DESCRIPTION OF PROPERTY | 56 | ||
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING | |||
AND
FINANCIAL
DISCLOSURES
|
56 | ||
DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS | 57 | ||
LEGAL PROCEEDINGS | 68 | ||
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT
|
68 | ||
TRANSACTIONS
WITH RELATED PERSONS, PROMOTERS AND CERTAIN
CONTROL PERSONS
|
73 | ||
MARKET FOR OUR COMMON STOCK | 74 | ||
DESCRIPTION OF SECURITIES | 77 | ||
EXPERTS | 79 | ||
LEGAL MATTERS | 79 | ||
WHERE YOU CAN FIND MORE INFORMATION | 79 | ||
FINANCIAL STATEMENTS | F-1 | ||
(1)
|
2,186,549
of such shares relate to shares of common stock underlying Series
A
Preferred Stock and common stock warrants which were issued to Oracle
and
affiliates on November 13, 2007 in exchange for the cancellation
of
$4,015,000 of principal amount of convertible promissory notes plus
interest, as amended, originally issued to Oracle on September 13,
2000.
The Company had previously registered the common stock underlying
such
convertible notes on a registration statement on Form S-1 Registration
Statement No. 333-135734 which was declared effective on August 7,
2006.
|
(2)
|
7,242,200
of such shares relate to shares of common stock underlying Series
A
Preferred Stock and common stock warrants which were issued to Lake
End
Capital LLC and SCO and affiliates on November 13, 2007 in exchange
for
the cancellation of $6,000,000 of principal amount of convertible
promissory notes plus interest originally issued to Lake End Capital
LLC
and SCO and affiliates on February 16, 2006 ($5,000,000), October
24, 2006
($500,000) and December 6, 2006, ($500,000). The Company had previously
registered the common stock underlying $5,000,000 of the convertible
notes
issued on a registration statement on Form S-1 Registration Statement
No.
333-135734, which was declared effective on August 7,
2006.
|
(4)
|
6,132,493
of such shares relate to shares of common stock underlying Series
A
Preferred Stock and common stock warrants acquired by new and certain
previously existing investors. Such shares include 2,499,998 shares
underlying Series A Preferred Stock and common stock warrants purchased
by
SCO and affiliates and 3,632,495 shares underlying Series A Preferred
Stock and common stock warrants purchased by new investors.
The issuance of such shares occurred in November 7, 2007 with regard
to 4,769,995 shares and February 4, 2008 with regard to 1,362,498
shares.
|
(4)
|
1,582,360
of such shares relate to common stock dividends which may be paid
on the
Series A Preferred Stock. The Series A Preferred Stock accrues
dividends at the rate of 6% per annum. Subject to certain
conditions being met, Access in its sole discretion may choose to
pay
these dividends in shares of common stock rather than in cash. The
common
stock dividend shares being registered represents anticipated dividends
on
the Series A Preferred Stock over 2 years assuming a fixed market
price of
$2.00 per share for Access’ common
stock.
|
(5)
|
772,728
of such shares relate to shares of common stock underlying common
stock
warrants acquired by Lake End Capital LLC and SCO and affiliates
in
October and December of 2005 for the aggregate issuance of $1,000,000
of
convertible promissory notes.
|
(6)
|
254,417
of
such shares
relate to shares of common stock underlying common stock warrants
paid to
Rodman & Renshaw, LLC, SCO Capital Partners LLC, and Lake End Capital
LLC as placement agent fees pursuant to the sale of the Series
A Preferred
Stock.
|
·
|
MuGard™
is our approved product for the management of oral mucositis, a frequent
side-effect of cancer therapy for which there is no established treatment.
The market for mucositis treatment is estimated to be in excess of
US$1
billion world-wide. MuGard, a proprietary nanopolymer formulation,
has
received marketing allowance in the U.S. from the Food & Drug
Administration (“FDA”).
|
·
|
Our
lead development candidate for the treatment of cancer is ProLindac™, a
nanopolymer DACH-platinum prodrug. ProLindac is currently in a Phase
2
clinical trial being conducted in the EU in patients with ovarian
cancer.
The DACH-platinum incorporated in ProLindac is the same active moiety
as
that in oxaliplatin (Eloxatin; Sanofi-Aventis), which has sales in
excess
of $2.0 billion.
|
·
|
Pre-clinical
development of Cobalamin™, our proprietary nanopolymer oral drug delivery
technology based on the natural vitamin B12 uptake mechanism. We
are
currently developing a product for the oral delivery of
insulin.
|
·
|
Pre-clinical
development of Angiolix®, a humanized monoclonal antibody which acts as an
anti-angiogenesis factor and is targeted to cancer cells, notably
breast,
ovarian and colorectal cancers.
|
·
|
Pre-clinical
development of Prodrax®, a non-toxic prodrug which is activated in the
hypoxic zones of solid tumors to kill cancer
cells.
|
·
|
Pre-clinical
development of Alchemix®, a chemotherapeutic agent that combines multiple
modes of action to overcome drug
resistance.
|
·
|
Pre-clinical
development of Cobalamin-mediated targeted
delivery.
|
·
|
Phenylbutyrate
(“PB”), an HDAC inhibitor and a differentiating agent, is a Phase 2
clinical candidate being developed in collaboration with Virium
Pharmaceuticals.
|
Compound
|
Originator
|
Technology
|
Indication
|
Clinical
Stage
(1)
|
||||
MuGard™
|
Access
|
Mucoadhesive
liquid
|
Mucositis
|
Marketing
clearance received
|
||||
ProLindacTM
(Polymer
Platinate,
AP5346) (2)
|
Access
– U London
|
Synthetic
polymer
|
Cancer
|
Phase
2
|
||||
Phenylbutyrate
(PB)
|
National
Institute
of
Health
|
Small
molecule
|
Cancer
|
Phase
2
|
||||
Oral
Insulin
|
Access
|
Cobalamin
|
Diabetes
|
Pre-clinical
|
||||
Oral
Delivery System
|
Access
|
Cobalamin
|
Various
|
Pre-clinical
|
||||
Angiolix®
|
Immunodex,
Inc.
|
Humanized
monoclonal
antibody
|
Cancer
|
Pre-clinical
|
||||
Prodrax®
|
Univ
London
|
Small
molecule
|
Cancer
|
Pre-clinical
|
||||
Alchemix®
|
DeMontford
Univ
|
Small
molecule
|
Cancer
|
Pre-clinical
|
||||
Cobalamin-Targeted
Therapeutics
|
Access
|
Cobalamin
|
Anti-tumor
|
Pre-clinical
|
||||
(1)
|
For
more information, see “Government Regulation” for description of clinical
stages.
|
(2)
|
Licensed
from the School of Pharmacy, The University of London. Subject to
a 1%
royalty and milestone payments on
sales.
|
|
Common
stock offered by Access:
|
None.
|
Common
stock offered by selling shareholders:
|
18,170,747
shares, which includes 11,666,195 shares issuable upon conversion
of
Series A Preferred Stock, 4,149,464 issuable upon exercise of warrants,
1,582,360 shares to be issued as dividends and 772,728 issuable upon
exercise of warrants as described
above.
|
Common
stock outstanding:
|
As
of March 6, 2008, 5,623,781 shares of our common stock were issued
and
outstanding.
|
Offering
Price:
|
To
be determined by the prevailing market price for the shares at the
time of
the sale or in negotiated
transactions.
|
Proceeds
to Access:
|
We
will not receive proceeds from the resale of shares by the selling
shareholders. If the warrants described herein are fully exercised
without
using any applicable cashless exercise provisions, we will receive
approximately $15,566,307 in cash from the warrant
holders.
|
Use
of proceeds:
|
We
will not receive any of the proceeds from the sale by any selling
shareholder of our common stock offered hereby, although in the event
that
the warrants are fully exercised without using any applicable cashless
exercise provisions, we will receive approximately $15,566,307 in
cash. We
intend to use these proceeds, if any, for general corporate
purposes.
|
OTC
Bulletin Board Symbol:
|
ACCP:OB
|
|
For
the Nine
Months
Ended
September
30
|
For
the Year Ended
December 31,
|
|||||||
2007
|
2006
|
2006
|
2005
|
2004
|
2003
|
2002
|
||
(in
thousands, except amounts per
share)
|
Consolidated
Statement of Operations and Comprehensive Loss Data:
|
Total
revenues
|
$ | 6 | $ | - | $ | - | $ | - | $ | - | $ | - | $ | 89 | ||||||||||||||
Operating
loss
|
(4,988 | ) | (4,129 | ) | (5,175 | ) | (9,622 | ) | (6,003 | ) | (5,426 | ) | (5,925 | ) | ||||||||||||||
Interest
and miscellaneous income
|
72 | 278 | 294 | 100 | 226 | 279 | 594 | |||||||||||||||||||||
Interest
and other expense
|
(3,277 | ) | (5,244 | ) | (7,436 | ) | (2,100 | ) | (1,385 | ) | (1,281 | ) | (1,278 | ) | ||||||||||||||
Unrealized
loss on fair value of warrants
|
- | (1,107 | ) | (1,107 | ) | - | - | - | - | |||||||||||||||||||
Income
tax benefit
|
- | - | 173 | 4,067 | - | - | - | |||||||||||||||||||||
Loss
from continuing operations
|
(8,193 | ) | (10,202 | ) | (13,251 | ) | (7,555 | ) | (7,162 | ) | (6,428 | ) | (6,520 | ) | ||||||||||||||
Discontinued
operations net of taxes
|
||||||||||||||||||||||||||||
($173
in 2006 and $4,067 in 2005)
|
- | - | 377 | 5,855 | (3,076 | ) | (507 | ) | (2,864 | ) | ||||||||||||||||||
Net
loss
|
(8,193 | ) | (10,202 | ) | (12,874 | ) | (1,700 | ) | (10,238 | ) | (6,935 | ) | (9,384 | ) | ||||||||||||||
Common
Stock Data:
|
||||||||||||||||||||||||||||
Net
loss per basic and
diluted
common share
|
$ | (2.31 | ) | $ | (2.89 | ) | $ | (3.65 | ) | $ | (0.53 | ) | $ | (3.38 | ) | $ | (2.61 | ) | $ | (3.58 | ) | |||||||
Weighted
average basic and
diluted
common shares
outstanding
|
3,544 | 3,531 | 3,532 | 3,237 | 3,032 | 2,653 | 2,621 | |||||||||||||||||||||
September
30,
|
December
31,
|
||||||
2007
|
2006
|
2006
|
2005
|
2004
|
2003
|
2002
|
|
(in
thousands)
|
Consolidated
Balance Sheet Data:
|
Cash,
cash equivalents and
short
term investments
|
$ | 1,176 | $ | 705 | $ | 4,389 | $ | 474 | $ | 2,261 | $ | 2,587 | $ | 9,776 | ||||||||||||||
Restricted
cash
|
- | - | - | 103 | 1,284 | 649 | 468 | |||||||||||||||||||||
Total
assets
|
3,500 | 7,073 | 6,426 | 7,213 | 11,090 | 11,811 | 19,487 | |||||||||||||||||||||
Deferred
revenue
|
1,167 | 173 | 173 | 173 | 1,199 | 1,184 | 1,199 | |||||||||||||||||||||
Convertible
notes, net of discount
|
16,906 | 17,608 | 8,833 | 7,636 | 13,530 | 13,530 | 13,530 | |||||||||||||||||||||
Total
liabilities
|
20,691 | 21,272 | 16,313 | 11,450 | 17,751 | 17,636 | 18,998 | |||||||||||||||||||||
Total
stockholders' equity (deficit)
|
(17,191 | ) | (14,199 | ) | (9,887 | ) | (4,237 | ) | (6,661 | ) | (5,825 | ) | 489 |
For
the Years Ended April 30,
|
||||||||||
2007
|
2006
|
2005
|
||||||||
(In
thousands, except per share data)
|
||||||||||
Consolidated
Statement of Operations and Comprehensive Loss Data
|
||||||||||
Total
revenues
|
$
|
1
|
$
|
1
|
$
|
-
|
||||
Operating
loss
|
(4,550
|
)
|
(4,108
|
)
|
(1,129
|
)
|
||||
Interest
and miscellaneous income
|
28
|
17
|
-
|
|||||||
Interest
and other expense
|
(2,969
|
)
|
(908
|
)
|
-
|
|||||
Income
tax
|
4
|
2
|
-
|
|||||||
Net
loss
|
(7,496
|
)
|
(5,002
|
)
|
(1,129
|
)
|
||||
Deemed
dividends on convertible preferred stock
|
-
|
(1,522
|
)
|
-
|
||||||
Net
loss applicable to common shareholders
|
(7,496
|
)
|
(6,524
|
)
|
(1,129
|
)
|
||||
Comprehensive
loss-foreign currency translation adjustment
|
-
|
-
|
(6
|
)
|
||||||
Comprehensive
loss
|
(7,496
|
)
|
(6,524
|
)
|
(1,135
|
)
|
||||
Common
Stock Data:
|
||||||||||
Net
loss per basic and diluted
common
share
|
$
|
(0.56
|
)
|
$
|
(0.47
|
)
|
$
|
(0.20
|
)
|
|
Weighted
average basic and
diluted
common shares
outstanding
|
14,278,247
|
14,274,365
|
5,576,845
|
As
of April 30,
|
|||||||
2007
|
2006
|
||||||
(In
thousands)
|
|||||||
Consolidated Balance
Sheet Data
|
|||||||
Cash,
cash equivalents and short term investments
|
$
|
5
|
$
|
1,588
|
|||
Restricted
cash
|
2
|
152
|
|||||
Total
assets
|
67
|
1,859
|
|||||
Current
liabilities
|
8,245
|
3,443
|
|||||
Total
liabilities
|
8,245
|
3,443
|
|||||
Total
stockholders' equity (deficit)
|
(8,178
|
)
|
(1,585
|
)
|
|
Unaudited
Pro Forma Condensed Combined
Consolidated
Statement of Operations Data:
|
For
the Twelve
Months
Ended
December
31, 2006
|
For
the Nine
Months
Ended
September
30, 2007
|
|||||
(in
thousands)
|
(in
thousands)
|
||||||
Total
revenues
|
$
|
1
|
$
|
7
|
|||
Total
expenses
|
9,727
|
7,531
|
|||||
Loss
from operations
|
(9,726
|
)
|
(7,524
|
)
|
|||
Interest
and miscellaneous income
|
322
|
84
|
|||||
Interest
and other expenses
|
(7,436
|
)
|
(3,304
|
)
|
|||
Change
in fair value of warrant liabilities
|
(4,038
|
)
|
5,807
|
|
|||
Net
loss before discontinued
operations
and before tax benefit
|
(20,916
|
)
|
(4,939
|
)
|
|||
Income
tax benefit
|
169
|
-
|
|||||
Loss
from continuing operations
|
(20,747
|
)
|
(4,939
|
)
|
|||
Discontinued
operations, net of
taxes
of $173,000
|
377
|
-
|
|||||
Net
loss
|
$
|
(20,370
|
)
|
$
|
(4,943
|
)
|
|
Unaudited
Pro Forma Condensed Combined
Consolidated
Balance Sheet:
|
As
of September 30, 2007
|
||||
(in
thousands)
|
|||||
Cash
and cash equivalents
|
$
|
663
|
|||
Short
term investments, at cost
|
515
|
||||
Total
current assets
|
1,361
|
||||
Property
and equipment, net
|
170
|
||||
Patents
net
|
752
|
||||
Total
assets
|
2,308
|
||||
Accounts
payables and accrued expenses
|
3,538
|
||||
Current
portion of long-term debt net of discount
|
11,406
|
||||
Long-term
debt
|
5,500
|
||||
Total
liabilities
|
22,921
|
||||
Additional
paid-in capital
|
77,172
|
||||
Notes
receivable from stockholders
|
(1,045
|
)
|
|||
Accumulated
deficit
|
(96,787
|
)
|
|||
Total
stockholders’ deficit
|
(20,613
|
)
|
|
•
|
unanticipated
issues in integrating information, communications and other
systems;
|
•
|
retaining
key employees;
|
•
|
consolidating
corporate and administrative
infrastructures;
|
•
|
the
diversion of management’s attention from ongoing business concerns;
and
|
•
|
coordinating
geographically separate
organizations.
|
·
|
some
or all of its drug candidates may be found to be unsafe or ineffective
or
otherwise fail to meet applicable regulatory standards or receive
necessary regulatory clearances;
|
·
|
its
drug candidates, if safe and effective, may be too difficult to develop
into commercially viable drugs;
|
·
|
it
may be difficult to manufacture or market its drug candidates on
a large
scale;
|
·
|
proprietary
rights of third parties may preclude it from marketing its drug
candidates; and
|
·
|
third
parties may market superior or equivalent
drugs.
|
●
|
A
mucoadhesive liquid technology product, MuGard™, has received marketing
approval by the FDA.
|
●
|
ProLindac™
is currently in a Phase 2 trial in
Europe.
|
●
|
ProLindac™
has been approved for an additional Phase 1 trial in the US by
the
FDA.
|
●
|
Phenylbutrate
is in planning stage for a Phase 2 trial in the United
States.
|
●
|
Cobalamin™
mediated delivery technology is currently in the pre-clinical
phase.
|
●
|
Angiolix®
is currently in the pre-clinical
phase.
|
●
|
Prodrax®
is currently in the pre-clinical
phase.
|
●
|
Alchemix®
is currently in the pre-clinical
phase.
|
●
|
Access
also has other products in the preclinical
phase.
|
•
|
Antigenics
and Regulon are developing liposomal platinum
formulations;
|
•
|
Spectrum
Pharmaceuticals and GPC Biotech are developing oral
platinum formulations;
|
•
|
Poniard
Pharmaceuticals is developing both i.v. and oral platinum
formulations;
|
•
|
Nanocarrier
and Debio are developing micellar nanoparticle platinum formulations;
and
|
|
•
|
American Pharmaceutical Partners, Cell Therapeutics, Daiichi, and Enzon are developing alternate drugs in | |
combination with polymers and other drug delivery systems. |
•
|
Exclusive
Patent and Know-how Sub-license Agreement between Somanta and
Immunodex, Inc. dated August 18, 2005, as amended;
|
|
•
|
Patent
and Know-how Assignment and License Agreement between Somanta and De
Montfort University dated March 20, 2003;
|
|
•
|
Patent
and Know-how Assignment and License Option Agreement between Somanta
and The School of Pharmacy, University of London dated March 16,
2004, as amended on September 21, 2005; and
|
|
|
||
•
|
The
Phenylbutyrate Co-Development and Sublicense Agreement
between Somanta and Virium Pharmaceuticals, Inc. dated
February 16, 2005, as amended.
|
·
|
third-party
payers' increasing challenges to the prices charged for medical products
and services;
|
·
|
the
trend toward managed health care in the United States and the concurrent
growth of HMOs and similar organizations that can control or significantly
influence the purchase of healthcare services and products;
and
|
·
|
legislative
proposals to reform healthcare or reduce government insurance
programs.
|
·
|
Mucoadhesive
technology in 2021,
|
·
|
ProLindac™
in 2021,
|
·
|
Phenylbutyrate
between 2011 and 2016,
|
·
|
Angiolix®
in 2015,
|
·
|
Alchemix®
in 2015,
|
·
|
Cobalamin
mediated technology between 2008 and
2019
|
Selling
Stockholder
|
Shares
Beneficially
Owned
Before
Offering
(1)
|
Percentage
of
Outstanding
Shares
Beneficially
Owned
Before
Offering
|
Shares
to
be Sold in the
Offering
|
Percentage
of
Outstanding
Shares
Beneficially
Owned
After
Offering
|
Mark
J. Alvino (2)
|
80,525
|
1.4%
|
9,091
|
1.3%
|
Beach
Capital LLC (3)
|
949,496
|
14.4%
|
608,587
|
5.7%
|
Brio
Capital LP (4)
|
75,000
|
1.3%
|
75,000
|
-
|
Catalytix
LDC Life Science
Hedge
AC (5)
|
24,999
|
*
|
24,999
|
-
|
Cobblestone
Asset Mangement LLC (6)
|
155,450
|
2.7%
|
125,000
|
*
|
Cranshire
Capital, LP (7)
|
250,000
|
4.3%
|
250,000
|
-
|
Credit
Suisse Securities (USA) LLC (8)
|
500,000
|
8.2%
|
500,000
|
-
|
Enable
Growth Partners LP (9)
|
249,999
|
4.3%
|
249,999
|
-
|
Howard
Fischer (10)
|
54,545
|
*
|
9,091
|
*
|
Edward
and Patricia Kelly (11)
|
99,999
|
1.8%
|
99,999
|
-
|
Lake
End Capital LLC (12)
|
1,988,784
|
26.1%
|
1,556,166
|
7.1%
|
Dennis
Lavalle (13)
|
45,000
|
*
|
45,000
|
-
|
David
P. Luci (14)
|
37,500
|
*
|
12,500
|
*
|
Midsummer
Investment, Ltd (15)
|
750,000
|
11.8%
|
750,000
|
-
|
Oracle
Institutional Partners LP (16)
|
390,828
|
6.5%
|
380,399
|
*
|
Oracle
Offshore Ltd. (17)
|
76,893
|
1.4%
|
71,886
|
*
|
Oracle
Partners, LP (18)
|
1,622,482
|
23.2%
|
1,374,831
|
4.4%
|
Perceptive
Life Sciences
Master
Fund Ltd (19)
|
999,999
|
15.1%
|
999,999
|
-
|
Rockmore
Investment
Master
Fund Ltd (20)
|
249,999
|
4.3%
|
249,999
|
-
|
Rodman
& Renshaw LLC (21)
|
109,000
|
1.9%
|
109,000
|
-
|
SAM
Oracle Investments, Inc (22)
|
389,169
|
6.5%
|
359,433
|
*
|
Schroder
& Co. Bank AG, Zurich (23)
|
125,000
|
2.2%
|
125,000
|
-
|
SCO
Capital Partners LLC (24)
|
11,033,426
|
66.2%
|
8,033,427
|
34.8%
|
SCO
Capital Partners LP (25)
|
999,999
|
15.1%
|
999,999
|
-
|
Total:
|
21,258,092
|
17,020,705
|
(1)
|
Applicable
percentage of ownership is based on 5,623,781 shares of common stock
outstanding as of March 6, 2008, together with securities exercisable
or
convertible into shares of common stock within 60 days of March 6,
2008,
for each stockholder. Beneficial ownership is determined in accordance
with Rule 13d-3(d) promulgated by the Commission under the Securities
and Exchange Act of 1934, as amended. Shares of common stock issuable
pursuant to options, warrants and convertible securities are treated
as
outstanding for computing the percentage of the person holding such
securities but are not treated as outstanding for computing the percentage
of any other person. Unless otherwise noted, each person or group
identified possesses sole voting and investment power with respect
to
shares, subject to community property laws where applicable. Shares
not
outstanding but deemed beneficially owned by virtue of the right
of a
person or group to acquire them within 60 days are treated as
outstanding only for purposes of determining the number of and percent
owned by such person or group. Unless a holder of Series A Cumulative
Convertible Preferred Stock either elected otherwise prior to the
purchase
of such preferred stock or elects otherwise upon not less than 61
days
prior written notice, its ability to convert its Series A Cumulative
Convertible Preferred Stock into common stock or to vote on an
as-if-converted to common stock basis is restricted pursuant to
a beneficial ownership cap to the extent that such conversion would
result
in the holder owning more than 4.99% of our issued and outstanding
common
stock or voting together with the common stock on an as-if-converted
to
common stock basis in respect of more than 4.99% of our issued and
outstanding common stock. The warrants issued in connection with
the
Series A Cumulative Convertible Preferred Stock are subject to a
similar
beneficial ownership cap restriction on their exercise. SCO Capital
Partners LLC, SCO Capital Partners, L.P. and Beach Capital LLC, have
elected not to be governed by these restrictions. For purposes of
the
table, beneficial ownership has been calculated as if there were
no such
beneficial ownership cap.
|
(2)
|
Mark
J. Alvino is Managing Director of Griffin Securities LLC. Mr. Alvino
is a
director of Access designated by SCO Capital Partners LLC pursuant
to an
agreement between SCO Capital Partners LLC and Access. Mr. Alvino
is known
to beneficially own warrants to purchase an aggregate of 55,525 shares
of
Access’ Common Stock and options to purchase 25,000 shares of Access’
Common Stock pursuant to the 2005 Equity Incentive
Plan.
|
(3)
|
Beach
Capital LLC is known to directly beneficially own warrants to purchase
an
aggregate of 435,197 shares of Access’ Common Stock and Series A Preferred
Stock which may be converted into an aggregate of 514,299 shares
of
Access’ Common Stock. Beach Capital LLC and affiliates (SCO Capital
Partners LP and SCO Capital Partners LLC) are known to beneficially
own
warrants to purchase an aggregate of 5,924,770 shares of Access’ Common
Stock and 7,077,100 shares of Common Stock issuable to them upon
conversion of Series A Preferred Stock. Steven H. Rouhandeh, in his
capacity as managing member of Beach Capital LLC has the power to
direct
the vote and disposition of the shares owned by Beach Capital
LLC. Beach Capital LLC has opted out of the beneficial
ownership cap described above. Each of Mr. Davis and Mr. Alvino,
Access’
directors and Mr. Davis an executive with SCO Capital Partners LLC,
disclaim beneficial ownership of such shares except to the extent
of his
pecuniary interest therein.
|
(4)
|
Brio
Capital LP is known to beneficially own an aggregate of warrants
to
purchase and aggregate of 25,000 shares of Access’ Common Stock and Series
A Preferred Stock which may be converted into an aggregate of 50,000
shares of Access’ Common Stock.
|
(5)
|
Catalytix
LDC Life Science Hedge AC is known to beneficially own warrants to
purchase an aggregate of 8,333 shares of Access’ Common Stock and Series A
Preferred Stock which may be converted into an aggregate of 16,666
shares
of Access’ Common Stock.
|
(6)
|
Cobblestone
Asset Management LLC is known to beneficially own an aggregate of
30,450
shares of Access’ Common Stock, warrants to purchase an aggregate of
41,667 shares of Access’ Common Stock and Series A Preferred Stock which
may be converted into an aggregate of 83,333 shares of Access’ Common
Stock.
|
(7)
|
Cranshire
Capital, LP is known to beneficially own warrants to purchase an
aggregate
of 83,333 shares of Access’ Common Stock and Series A Preferred Stock
which may be converted into an aggregate of 166,667 shares of Access’
Common Stock. Michael P. Koplin, the president of Downsview Capital,
Inc.,
the general partner of Cranshire Capital, L.P., has sole voting control
and investment discretion over securities held by Cranshire Capital,
L.P.
Each of Michael P. Koplin and Downsview Capital, Inc. disclaims beneficial
ownership of shares held by Cranshire Capital,
L.P.
|
(8)
|
Credit
Suisse Securities (USA) LLC is known to beneficially own warrants
to
purchase an aggregate of 166,667 shares of Access’ Common Stock and Series
A Preferred Stock which may be converted into an aggregate of 333,333
shares of Access’ Common Stock.
|
(9)
|
Enable
Growth Partners LP is known to beneficially own warrants to purchase
an
aggregate of 83,333 shares of Access’ Common Stock and Series A Preferred
Stock which may be converted into an aggregate of 166,666 shares
of
Access’ Common Stock.
|
(10)
|
Howard
Fischer is known to beneficially own warrants to purchase an aggregate
of
54,545 shares of Access’ Common
Stock.
|
(11)
|
Edward
and Patricia Kelly are known to beneficially own warrants to purchase
an
aggregate of 33,333 shares of Access’ Common Stock and Series A Preferred
Stock which may be converted into an aggregate of 66,666 shares of
Access’
Common Stock.
|
(12)
|
Lake
End Capital LLC is known to beneficially own warrants to purchase
an
aggregate of 1,195,717 shares of Access’ Common Stock and Series A
Preferred Stock which may be converted into an aggregate of 793,067
shares
of Access’ Common Stock. Lake End Capital LLC and Mr. Davis are known to
beneficially own warrants and options to purchase an aggregate of
1,832,357 shares of Access’ Common Stock and 793,067 shares of Common
Stock issuable upon conversion of Series A Preferred Stock. Jeffrey
B.
Davis, in his capacity as managing member of Lake End Capital LLC,
has the
power to direct the vote and disposition of the shares owned by Lake
End
Capital LLC. Mr. Davis is President of SCO Securities LLC, a wholly-owned
subsidiary of SCO Financial Group LLC. Mr. Davis is a director of
Access
designated by SCO Capital Partners LLC pursuant to an agreement between
SCO Capital Partners LLC and
Access.
|
(13)
|
Dennis
Lavalle is known to beneficially own warrants to purchase an aggregate
of
15,000 shares of Access’ Common Stock and Series A Preferred Stock which
may be converted into an aggregate of 30,000 shares of Access’ Common
Stock.
|
(14)
|
David
P. Luci is known to beneficially own warrants and options to purchase
an
aggregate of 29,167 shares of Access’ Common Stock and 8,333 shares of
Common Stock issuable upon conversion of Series A Preferred
Stock.
|
(15)
|
Midsummer
Investment, Ltd. is known to beneficially own warrants to purchase
an
aggregate of 250,000 shares of Access’ Common Stock and Series A Preferred
Stock which may be converted into an aggregate of 500,000 shares
of
Access’ Common Stock.
|
(16)
|
Oracle
Institutional Partners LP is known to beneficially own an aggregate
of
10,429 shares of Access’ Common Stock, warrants to purchase an aggregate
of 126,800 shares of Access’ Common Stock and Series A Preferred Stock
which may be converted into an aggregate of 253,599 shares of Access’
Common Stock. Larry N. Feinberg is a partner in Oracle Partners,
L.P.
Oracle Partners, L.P. and affiliates (Oracle Institutional Partners,
L.P.,
Oracle Investment Management, Inc., SAM Oracle Fund, Inc. and Mr.
Feinberg) are known to beneficially own an aggregate of 292,823 shares
of
Access’ Common Stock, warrants to purchase an aggregate of 728,850 shares
of Access’ Common Stock and Series A Preferred Stock which may be
converted into an aggregate of 1,457,699 shares of Access’ Common
Stock.
|
(17)
|
Oracle
Offshore Ltd is known to beneficially own an aggregate of 5,007 shares
of
Access’ Common Stock, warrants to purchase an aggregate of 23,962 shares
of Access’ Common Stock and Series A Preferred Stock which may be
converted into an aggregate of 47,924 shares of Access’ Common Stock.
Larry N. Feinberg is a partner in Oracle Partners, L.P. Oracle Partners,
L.P. and affiliates (Oracle Institutional Partners, L.P., Oracle
Investment Management, Inc., SAM Oracle Fund, Inc. and Mr. Feinberg)
are
known to beneficially own an aggregate of 292,823 shares of Access’ Common
Stock, warrants to purchase an aggregate of 728,850 shares of Access’
Common Stock and Series A Preferred Stock which may be converted
into an
aggregate of 1,457,699 shares of Access’ Common
Stock.
|
(18)
|
Oracle
Partners, LP is known to beneficially own an aggregate of 247,651
shares
of Access’ Common Stock, warrants to purchase an aggregate of 458,277
shares of Access’ Common Stock and Series A Preferred Stock which may be
converted into an aggregate of 916,554 shares of Access’ Common Stock.
Larry N. Feinberg is a partner in Oracle Partners, L.P. Oracle Partners,
L.P. and affiliates (Oracle Institutional Partners, L.P., Oracle
Investment Management, Inc., SAM Oracle Fund, Inc. and Mr. Feinberg)
are
known to beneficially own an aggregate of 292,823 shares of Access’ Common
Stock, warrants to purchase an aggregate of 728,850 shares of Access’
Common Stock and Series A Preferred Stock which may be converted
into an
aggregate of 1,457,699 shares of Access’ Common
Stock.
|
(19)
|
Perceptive
Life Sciences Master Fund Ltd is known to beneficially own warrants
to
purchase an aggregate of 333,333 shares of Access’ Common Stock and Series
A Preferred Stock which may be converted into an aggregate of 666,666
shares of Access’ Common Stock.
|
(20)
|
Rockmore
Investment Master Fund Ltd is known to beneficially own warrants
to
purchase an aggregate of 83,333 shares of Access’ Common Stock and Series
A Preferred Stock which may be converted into an aggregate of 166,666
shares of Access’ Common Stock. Rockmore Capital, LLC (“Rockmore Capital”)
and Rockmore Partners, LLC (“Rockmore Partners”), each a limited liability
company formed under the laws of the State of Delaware, serve as
the
investment manager and general partner, respectively, to Rockmore
(US) LP,
a Delaware limited partnership, which invests all of its assets through
Rockmore Investment Master Fund Ltd., an exempted company formed
under the
laws of Bermuda (“Rockmore Master Fund”). By reason of such relationships,
Rockmore Capital and Rockmore Partners may be deemed to share dispositive
power over shares of our common stock owned by Rockmore Master Fund.
Rockmore Capital and Rockmore Partners disclaim beneficial ownership
of
such shares of our common stock. Rockmore Partners has delegated
authority
to Rockmore Capital regarding portfolio management decisions with
respect
to the shares of common stock owned by Rockmore Master Fund and,
as of
December 10, 2007, Mr. Bruce T. Bernstein and Mr. Brian Daly, as
officers
of Rockmore Capital, are responsible for the portfolio management
decisions of the shares of common stock owned by Rockmore Master
Fund. By
reason of such authority, Messsrs. Bernstein and Daly may be deemed
to
share dispositive power over the shares of our common stock owned
by
Rockmore Master Fund. Messrs. Bernstein and Daly disclaim beneficial
ownership of such shares of our common stock and neither of such
persons
has any legal right to maintain such authority. No other person has
sole
or shared voting or dispositive power with respect to the shares
of our
common stock as those terms are used for purposes under Regulation
13D-G
of the Securities Exchange Act of 1934, as amended. No person or
“group”
(as that term is used in Section 13(d) of the Securities Act of 1934,
as
amended, or the SEC’s Regulation 13D-G) controls Rockmore Master
Fund.
|
(21)
|
Rodman
& Renshaw LLC is known to beneficially own warrants to purchase an
aggregate of 109,000 shares of Access’ Common
Stock.
|
(22)
|
SAM
Oracle Investments, Inc. is known to beneficially own an aggregate
of
29,736 shares of Access’ Common Stock, warrants to purchase an aggregate
of 119,811 shares of Access’ Common Stock and Series A Preferred Stock
which may be converted into an aggregate of 239,622 shares of Access’
Common Stock. Larry N. Feinberg is a partner in Oracle Partners,
L.P.
Oracle Partners, L.P. and affiliates (Oracle Institutional Partners,
L.P.,
Oracle Investment Management, Inc., Sam Oracle Fund, Inc. and Mr.
Feinberg) are known to beneficially own an aggregate of 292,823 shares
of
Access’ Common Stock, warrants to purchase an aggregate of 728,850 shares
of Access’ Common Stock and Series A Preferred Stock which may be
converted into an aggregate of 1,457,699 shares of Access’ Common
Stock.
|
(23)
|
Schroder
& Co. Bank AG, Zurich is known to beneficially own warrants to
purchase an aggregate of 41,667 shares of Access’ Common Stock and Series
A Preferred Stock which may be converted into an aggregate of 83,333
shares of Access’ Common Stock.
|
(24)
|
SCO
Capital Partners LLC is known to directly beneficially own warrants
to
purchase an aggregate of 5,156,240 shares of Access’ Common Stock and
Series A Preferred Stock which may be converted into an aggregate
of
5,896,135 shares of Access’ Common Stock. SCO Capital Partners LLC and
affiliates (SCO Capital Partners, L.P. and Beach Capital LLC) are
known to
beneficially own warrants to purchase an aggregate of 5,924,770 shares
of
Access’ Common Stock and 7,077,100 shares of Common Stock issuable to them
upon conversion of Series A Preferred Stock. Steven H. Rouhandeh,
in his
capacity as chairman and managing member of SCO Capital Partners
LLC, has
the power to direct the vote and disposition of the shares owned
by SCO
Capital Partners LLC. SCO Capital Partners LLC has opted out of
the beneficial ownership cap described
above.
|
(25)
|
SCO
Capital Partners, L.P. is known to directly beneficially own warrants
to
purchase an aggregate of 333,333 shares of Access’ Common Stock and Series
A Preferred Stock which may be converted into an aggregate of 666,666
shares of Access’ Common Stock. SCO Capital Partners, L.P. and affiliates
(SCO Capital Partners LLC and Beach Capital LLC) are known to beneficially
own warrants to purchase an aggregate of 5,924,770 shares of Access’
Common Stock and 7,077,100 shares of Common Stock issuable to them
upon
conversion of Series A Preferred Stock. Steven H. Rouhandeh, in his
capacity as managing member of the entity that serves as general
partner
of SCO Capital Partners, L.P. has the power to direct the vote and
disposition of the shares owned by SCO Capital Partners, L.P. SCO
Capital
Partners, L.P. has opted out of the beneficial ownership cap described
above.
|
-
|
a
block trade in which the broker-dealer so engaged will attempt to
sell the
shares as agent but may position and resell a portion of the block
as
principal to facilitate the transaction (including crosses in which
the
same broker acts as agent for both sides of the
transaction);
|
-
|
purchases
by a broker-dealer as principal and resale by such broker-dealer,
including resales for its account, pursuant to this
prospectus;
|
-
|
ordinary
brokerage transactions and transactions in which the broker solicits
purchases;
|
-
|
through
options, swaps or derivatives;
|
-
|
in
privately negotiated transactions;
|
-
|
in
making short sales or in transactions to cover short sales;
and
|
-
|
put
or call option transactions relating to the
shares.
|
-
|
through
the writing or settlement of options or other hedging transactions,
whether through an options exchange
|
-
|
a
combination of any such methods of sale;
or
|
-
|
any
other method permitted pursuant to applicable
law.
|
-
|
the
name of each such selling security holder and of the participating
broker-dealer(s);
|
-
|
the
number of shares involved;
|
-
|
the
initial price at which the shares were
sold;
|
-
|
the
commissions paid or discounts or concessions allowed to the
broker-dealer(s), where applicable;
|
-
|
that
such broker-dealer(s) did not conduct any investigation to verify
the
information set out or incorporated by reference in this prospectus;
and
|
-
|
other
facts material to the transactions.
|
·
|
MuGard™
is our approved product for the management of oral mucositis, a frequent
side-effect of cancer therapy for which there is no established treatment.
The market for mucositis treatment is estimated to be in excess of
US$1
billion world-wide. MuGard, a proprietary nanopolymer formulation,
has
received marketing allowance in the U.S. from the Food & Drug
Administration (“FDA”).
|
·
|
Our
lead development candidate for the treatment of cancer is ProLindac™, a
nanopolymer DACH-platinum prodrug. ProLindac is currently in a Phase
2
clinical trial being conducted in the EU in patients with ovarian
cancer.
The DACH-platinum incorporated in ProLindac is the same active moiety
as
that in oxaliplatin (Eloxatin; Sanofi-Aventis), which has sales in
excess
of $2.0 billion.
|
·
|
Pre-clinical
development of Cobalamin™, our proprietary nanopolymer oral drug delivery
technology based on the natural vitamin B12 uptake mechanism. We
are
currently developing a product for the oral delivery of
insulin.
|
·
|
Pre-clinical
development of Angiolix®, a humanized monoclonal antibody which acts as an
anti-angiogenesis factor and is targeted to cancer cells, notably
breast,
ovarian and colorectal cancers.
|
·
|
Pre-clinical
development of Prodrax®, a non-toxic prodrug which is activated in the
hypoxic zones of solid tumors to kill cancer
cells.
|
·
|
Pre-clinical
development of Alchemix®, a chemotherapeutic agent that combines multiple
modes of action to overcome drug
resistance.
|
·
|
Pre-clinical
development of Cobalamin-mediated targeted
delivery.
|
·
|
Phenylbutyrate
(“PB”), an HDAC inhibitor and a differentiating agent, is a Phase 2
clinical candidate being developed in collaboration with Virium
Pharmaceuticals.
|
Compound
|
Originator
|
Technology
|
Indication
|
Clinical
Stage
(1)
|
||||
MuGard™
|
Access
|
Mucoadhesive
liquid
|
Mucositis
|
Marketing
clearance received
|
||||
ProLindacTM
(Polymer
Platinate,
AP5346) (2)
|
Access
– U London
|
Synthetic
polymer
|
Cancer
|
Phase
2
|
||||
Phenylbutyrate
(PB)
|
National
Institute
of
Health
|
Small
molecule
|
Cancer
|
Phase
2
|
||||
Oral
Insulin
|
Access
|
Cobalamin
|
Diabetes
|
Pre-clinical
|
Oral
Delivery System
|
Access
|
Cobalamin
|
Various
|
Pre-clinical
|
||||
Angiolix®
|
Immunodex,
Inc.
|
Humanized
monoclonal
antibody
|
Cancer
|
Pre-clinical
|
||||
Prodrax®
|
Univ
London
|
Small
molecule
|
Cancer
|
Pre-clinical
|
||||
Alchemix®
|
DeMontford
Univ
|
Small
molecule
|
Cancer
|
Pre-clinical
|
||||
Cobalamin-Targeted
Therapeutics
|
Access
|
Cobalamin
|
Anti-tumor
|
Pre-clinical
|
||||
(1)
|
For
more information, see “Government Regulation” for description of clinical
stages.
|
(2)
|
Licensed
from the School of Pharmacy, The University of London. Subject to
a 1%
royalty and milestone payments on
sales.
|
·
|
costs
for product manufacturing for a new ProLindac clinical trial expected
to
start in 2008 ($214,000);
|
·
|
higher
salary and related cost due to the hiring of additional scientific
staff
($30,000); and
|
·
|
other
net increases ($25,000).
|
·
|
higher
investor relations expenses ($149,000) due to our increased investor
relations efforts;
|
·
|
higher
salary related expenses due to stock option expenses ($156,000);
and
|
·
|
higher
salary expenses ($65,000).
|
·
|
lower
patent expenses ($90,000);
|
·
|
lower
professional fees ($59,000); and
|
·
|
other
net decreases ($21,000).
|
·
|
lower
costs for product manufacturing for ProLindac ($198,000). Product
manufacturing was completed early in 2006 which we believe is adequate
to
supply drug product for our current ovarian cancer
trial;
|
·
|
lower
costs of clinical trials for ProLindac ($170,000). We incurred start-up
costs for the clinical trial in early 2006;
and
|
·
|
other
net decreases ($53,000).
|
·
|
higher
salary and related cost due to the hiring of additional scientific
staff
($121,000); and
|
·
|
higher
scientific consulting costs
($63,000).
|
·
|
higher
salary related expenses due mainly to stock option expenses
($580,000);
|
·
|
higher
investor relations expenses ($368,000) due to our increased investor
relations efforts;
|
·
|
higher
salary and related costs ($178,000);
and
|
·
|
higher
travel costs ($58,000).
|
·
|
lower
patent expenses ($45,000); and
|
·
|
other
net decreases ($16,000).
|
·
|
Salary
expenses due to the separation agreement in 2005 with our former
CEO
($909,000);
|
·
|
Professional
fees for investment strategies and fairness opinions in 2005
($397,000);
|
·
|
Legal
fees ($313,000);
|
·
|
Patent
and license fees ($194,000);
|
·
|
Rent
($113,000);
|
·
|
Compensation
paid to Chairman in 2005 ($140,000)
and
|
·
|
Other
net decreases ($41,000).
|
·
|
Salary
related costs due to the expensing of stock options ($180,000);
and
|
·
|
Investor/public
relations fees ($102,000).
|
·
|
Expenses
due to the separation agreement with our former CEO
($909,000);
|
·
|
Professional
fees for investment banking and financing decisions
($397,000);
|
·
|
Higher
legal fees due to changes in our convertible debt and legal fees
associated with merger candidates
($161,000); and
|
·
|
Royalty
license fee ($150,000).
|
·
|
Lower
investor relations costs ($90,000);
|
·
|
Lower
patent expenses ($61,000); and
|
·
|
Lower
net other increases ($27,000).
|
·
|
the
successful development and commercialization of ProLindac™, MuGard™ and
our other product candidates;
|
·
|
the
ability to convert, repay or restructure our outstanding convertible
notes
and debentures;
|
·
|
the
ability to integrate Somanta Pharmaceuticals, Inc. assets and programs
with ours;
|
·
|
the
ability to establish and maintain collaborative arrangements with
corporate partners for the research, development and commercialization
of
products;
|
·
|
continued
scientific progress in our research and development
programs;
|
·
|
the
magnitude, scope and results of preclinical testing and clinical
trials;
|
·
|
the
costs involved in filing, prosecuting and enforcing patent
claims;
|
·
|
the
costs involved in conducting clinical
trials;
|
·
|
competing
technological developments;
|
·
|
the
cost of manufacturing and scale-up;
|
·
|
the
ability to establish and maintain effective commercialization arrangements
and activities; and
|
·
|
successful
regulatory filings.
|
(in
thousands)
|
Twelve
Months ended
December
31,
|
Nine
Months ended
September
30,
|
Inception
To
Date
(1)
|
Project
|
2006
|
2005
|
2007
|
Polymer
Platinate
(ProLindac™)
|
$ | 2,043 | $ | 2,653 | $ | 1,433 | $ | 21,087 | ||||||||
Mucoadhesive
Liquid
Technology
(MLT)
|
10 | - | 21 | 1,511 | ||||||||||||
Others
(2)
|
- | 130 | 78 | 5,122 | ||||||||||||
Total
|
$ | 2,053 | $ | 2,783 | $ | 1,532 | $ | 27,720 | ||||||||
(1)
|
Cumulative
spending from inception of the Company or project through September
30,
2007.
|
(2)
|
Includes: Vitamin
Mediated Targeted Delivery, carbohydrate targeting, amlexanox cream
and
gel and other related projects.
|
·
|
MuGard™
is our approved product for the management of oral mucositis, a frequent
side-effect of cancer therapy for which there is no established treatment.
The market for mucositis treatment is estimated to be in excess of
US$1
billion world-wide. MuGard, a proprietary nanopolymer formulation,
has
received marketing allowance in the U.S. from the Food & Drug
Administration (“FDA”).
|
·
|
Our
lead development candidate for the treatment of cancer is ProLindac™, a
nanopolymer DACH-platinum prodrug. ProLindac is currently in a Phase
2
clinical trial being conducted in the EU in patients with ovarian
cancer.
The DACH-platinum incorporated in ProLindac is the same active moiety
as
that in oxaliplatin (Eloxatin; Sanofi-Aventis), which has sales in
excess
of $2.0 billion.
|
·
|
Pre-clinical
development of Cobalamin™, our proprietary nanopolymer oral drug delivery
technology based on the natural vitamin B12 uptake mechanism. We
are
currently developing a product for the oral delivery of
insulin.
|
·
|
Pre-clinical
development of Angiolix®, a humanized monoclonal antibody which acts as an
anti-angiogenesis factor and is targeted to cancer cells, notably
breast,
ovarian and colorectal cancers.
|
·
|
Pre-clinical
development of Prodrax®, a non-toxic prodrug which is activated in the
hypoxic zones of solid tumors to kill cancer
cells.
|
·
|
Pre-clinical
development of Alchemix®, a chemotherapeutic agent that combines multiple
modes of action to overcome drug
resistance.
|
·
|
Pre-clinical
development of Cobalamin-mediated targeted
delivery.
|
·
|
Phenylbutyrate
(“PB”), an HDAC inhibitor and a differentiating agent, is a Phase 2
clinical candidate being developed in collaboration with Virium
Pharmaceuticals.
|
Compound
|
Originator
|
Technology
|
Indication
|
Clinical
Stage
(1)
|
||||
MuGard™
|
Access
|
Mucoadhesive
liquid
|
Mucositis
|
Marketing
clearance received
|
||||
ProLindacTM
(Polymer
Platinate,
AP5346) (2)
|
Access
– U London
|
Synthetic
polymer
|
Cancer
|
Phase
2
|
||||
Phenylbutyrate
(PB)
|
National
Institute
of
Health
|
Small
molecule
|
Cancer
|
Phase
2
|
||||
Oral
Insulin
|
Access
|
Cobalamin
|
Diabetes
|
Pre-clinical
|
||||
Oral
Delivery System
|
Access
|
Cobalamin
|
Various
|
Pre-clinical
|
||||
Angiolix®
|
Immunodex,
Inc.
|
Humanized
monoclonal
antibody
|
Cancer
|
Pre-clinical
|
Prodrax®
|
Univ
London
|
Small
molecule
|
Cancer
|
Pre-clinical
|
||||
Alchemix®
|
DeMontford
Univ
|
Small
molecule
|
Cancer
|
Pre-clinical
|
||||
Cobalamin-Targeted
Therapeutics
|
Access
|
Cobalamin
|
Anti-tumor
|
Pre-clinical
|
||||
(1)
|
For
more information, see “Government Regulation” for description of clinical
stages.
|
(2)
|
Licensed
from the School of Pharmacy, The University of London. Subject to
a 1%
royalty and milestone payments on
sales.
|
|
|
•
|
A
patent covering a method of inhibiting rapid tumor growth issued
in the
U.S. that expires on March 14, 2014 with foreign counterparts in
Austria, Australia, Canada, Germany, European Union, Spain, Israel,
New
Zealand and South Africa;
|
•
|
A
patent covering a method of treating brain cancer, leukemia, prostate
cancer, breast cancer, skin cancer and non-small cell lung cancer
issued
in the U.S. that expires on June 3, 2014 with foreign counterparts
in
Austria, Australia, Canada, Germany, European Union, Spain, Israel,
Japan,
New Zealand, Portugal and South
Africa;
|
•
|
A
patent covering a method of treating brain cancer, skin cancer, benign
enlarged prostate and a cervical infection issued in the U.S. that
expires
on February 25, 2014 with foreign counterparts in Austria, Australia,
Canada, Germany, European Union, Spain, Israel, Japan, New Zealand,
Portugal and South Africa;
|
•
|
A
patent covering a method of inducing the production of TGF alpha
(which
slows the growth of cancer cells) issued in the U.S. that expires
on
January 13, 2015 with foreign counterparts in Austria, Australia,
Canada,
Germany, European Union, Spain, Israel, Japan, New Zealand, Portugal
and
South Africa;
|
•
|
A
patent covering a pharmaceutical composition for treating or preventing
a
cancerous condition issued in the U.S. that expires on January 20,
2015
with foreign counterparts in Austria, Australia, Canada, Germany,
European
Union, Spain, Israel, Japan, New Zealand, Portugal and South
Africa;
|
•
|
A
patent covering a method of inducing the differentiation of a cell
issued
in the U.S. that expires on June 3, 2014 with foreign counterparts
in
Austria, Australia, Canada, Germany, European Union, Spain, Israel,
Japan,
New Zealand, Portugal and South
Africa;
|
•
|
A
patent covering a method of treating brain cancer, non-small cell
lung
cancer, prostate cancer, skin cancer, brain tumors, cancers of the
blood,
lung cancer and breast cancer issued in the U.S. that expires on
August
26, 2014 with foreign counterparts in Austria, Australia, Canada,
Germany,
European Union, Spain, Israel, Japan, New Zealand, Portugal and South
Africa;
|
•
|
A
patent covering a method of inhibiting the growth of rapidly growing
nonmalignant or malignant tumor cells issued in the U.S. that expires
on
March 2, 2016 with foreign counterparts in Austria, Australia, Canada,
Germany, European Union, Spain, Israel, Japan, New Zealand, Portugal
and
South Africa;
|
•
|
A
patent covering a method of sensitizing a subject to radiation therapy
or
chemotherapy and a method of treating brain cancer, leukemia, non-small
cell lung cancer, skin cancer, cancers of the blood, lung cancer,
or renal
cancer issued in the U.S. that expires on December 1, 2015 with foreign
counterparts in Austria, Australia, Canada, Germany, European Union,
Spain, Israel, Japan, New Zealand, Portugal and South
Africa;
|
•
|
A
patent covering a method of treating brain cancer, non-small cell
lung
cancer, prostate cancer, skin cancer, cancers of the blood, breast
cancer,
benign prostate enlargement, cervical infection, bladder cancer,
kidney
cancer, colon cancer, or nose cancer issued in the U.S. that expires
on
March 16, 2016 with foreign counterparts in Austria, Australia, Canada,
Germany, European Union, Spain, Israel, Japan, New Zealand, Portugal
and
South Africa;
|
•
|
A
patent covering a method of inducing the production of hemoglobin
(blood)
and a method of treating a pathology associated with abnormal hemoglobin
(blood) activity issued in the U.S. that expires on January 27, 2015
with
foreign counterparts in Austria, Australia, Canada, Germany, European
Union, Spain, Israel, Japan, New Zealand, Portugal and South
Africa;
|
•
|
A
patent covering a method of preventing prostate cancer, brain cancer,
skin
cancer, cancers of the blood, breast cancer, non-small cell lung
cancer,
or renal cancer issued in the U.S. that expires on August 5, 2014
with
foreign counterparts in Austria, Australia, Canada, Germany, European
Union, Spain, Israel, Japan, New Zealand, Portugal and South Africa;
and
|
•
|
A
patent covering a method of inhibiting the production of cancer in
a cell
issued in the U.S. that expires on March 14, 2011, June 3, 2013 or
March
7, 2014, depending on the subject matter disclosed in the priority
applications with foreign counterparts in Austria, Australia, Canada,
Germany, European Union, Spain, Israel, Japan, New Zealand, Portugal
and
South Africa.
|
·
|
Synthetic
Polymer Targeted Drug Delivery
Technology;
|
·
|
Cobalamin™-Mediated
Oral Delivery Technology;
|
·
|
Cobalamin™-Mediated
Targeted Delivery Technology;
|
·
|
Angiolix®;
|
·
|
Prodrax®;
and
|
·
|
Alchemix®.
|
●
|
passive
tumor targeting involves transporting anti-cancer agents through
the
bloodstream to tumor cells using a “carrier” molecule. Many
different carrier molecules, which can take a variety of forms
(micelles,
nanoparticles, liposomes and polymers), are being investigated as
each provides advantages such as specificity and protection of
the
anti-cancer drug from degradation due to their structure, size
(molecular
weights) and particular interactions with tumor cells. Our polymer
platinate program is a passive tumor targeting
technology.
|
●
|
active
tumor targeting involves attaching an additional fragment to the
anticancer drug and the carrier molecule to create a new “targeted” agent
that will actively seek a complementary surface receptor to which
it binds
(preferentially located on the exterior of the tumor cells). The
theory is
that the targeting of the anti-cancer agent through active means
to the
affected cells should allow more of the anti-cancer drug to enter
the
tumor cell, thus amplifying the response to the treatment and reducing
the
toxic effect on bystander, normal
tissue.
|
–
|
folate
conjugates of polymer therapeutics, to enhance tumor delivery by
targeting
folate receptors, which are upregulated in certain
tumor types with two U.S. and two European patent
applications;
|
–
|
the
use of vitamin B12 to target the transcobalamin II receptor which
is
upregulated in numerous diseases including cancer, rheumatoid
arthritis, certain neurological and autoimmune disorders with two
U.S.
patents and three U.S. and four European patent applications;
and
|
–
|
oral
delivery of a wide variety of molecules which cannot otherwise
be orally
administered, utilizing the active transport
mechanism
which transports vitamin B12 into the
systemic circulation with six U.S. patents and two European patents
and
one U.S. and one European patent
application
|
·
|
Mucoadhesive
technology in 2021,
|
·
|
ProLindac™
in 2021,
|
·
|
Cobalamin
mediated technology between 2008 and
2019
|
Steven H. Rouhandeh | 50 | Chairman of the Board |
Jeffrey B. Davis | 44 | Chief Executive Officer, Director |
Rosemary
Mazanet, M.D., Ph.D.
|
52
|
Vice
Chairman
|
Esteban Cvitkovic, M.D. | 58 | Vice Chairman – Europe |
Mark J. Ahn, Ph.D. | 45 | Director |
Mark J. Alvino | 40 | Director |
Stephen B. Howell, M.D. | 63 | Director |
David P. Luci | 41 | Director |
John J. Meakem, Jr. | 71 | Director |
David P. Nowotnik, Ph.D | 58 | Senior Vice President Research & Development |
Phillip S. Wise | 49 | Vice President, Business Development & Strategy |
Stephen B. Thompson | 54 | Vice President, Chief Financial Officer, Treasurer, |
Secretary |
Name
and Principal Position
(7)
|
Year
|
Salary
($) (1)
|
Bonus
($)
|
Stock
Awards
($)
(2)
|
Option
Awards ($)
(3)
|
All
Other Compensation
(4)
|
Total
($)
|
Rosemary
Mazanet(5)(8)
Acting
CEO
|
2006
2005
|
$
|
357,385217,500
|
$
|
100,00030,000
|
$
|
-
-
|
|
$
|
81,464168,468
|
$
|
2,5941,297
|
$
|
541,443248,797
|
||||||||||||||
Kerry
P. Gray(6)
Former
President and CEO
|
2005
|
|
$
|
133,332
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
3,505
|
$
|
136,837
|
||||||||||||||
David
P. Nowotnik, Ph.D.
Senior
Vice President Research
and
Development
|
20062005
|
$
|
253,620250,710
|
$
|
20,00025,408
|
$
|
-24,154
|
$
|
40,73267,619
|
$
|
7,1527,094
|
$
|
321,504374,985
|
|||||||||||||||
Phillip
S. Wise(7)
Vice
President, Business
Development
|
2006
|
$
|
116,667
|
$
|
25,000
|
$
|
-
|
$
|
40,732
|
$
|
358
|
$
|
182,757
|
|||||||||||||||
Stephen
B. Thompson
Vice
President, Chief Financial Officer
|
20062005
|
$
|
154,080152,310
|
$
|
20,00015,435
|
$
|
-
14,704
|
$
|
40,73242,262
|
$
|
4,5084,455
|
$
|
219,320229,166
|
(1)
|
Includes
amounts deferred under Access’ 401(k)
Plan.
|
(2)
|
There
were no stock awards granted in 2006 and no restricted stock outstanding
at December 31, 2006.
|
(3)
|
The
value listed in the above table represents the fair value of the
options
granted in prior years that were recognized in 2006 under FAS 123R.
Fair
value is calculated as of the grant date using a Black-Sholes
option-pricing model. The determination of the fair value of share-based
payment awards made on the date of grant is affected by Access’ stock
price as well as assumptions regarding a number of complex and subjective
variables. Access’ assumptions in determining fair value are described in
note 10 to Access’ audited financial statements for the year ended
December 31, 2006, included in Access’ Annual Report on Form
10-KSB.
|
(4)
|
Amounts
reported for fiscal years 2006 and 2005 consist of: (i) amounts Access
contributed to its 401(k) Plan with respect to each named individual,
(ii)
amounts Access paid for group term life insurance for each named
individual, and (iii) for Mr. Gray, premiums paid by Access each
year for
life insurance for Mr. Gray.
|
(5)
|
Amounts
listed in 2006 and 2005 for Dr. Mazanet indicate compensation paid
to her
in connection with her services as Access’ Acting CEO commencing on May
11, 2005.
|
(6)
|
Amounts
listed in 2005 for Mr. Gray indicate compensation paid to him in
connection with his services as Access’ President and CEO through May 10,
2005. In addition to such amounts listed in the table above,
Mr. Gray also received a total of $333,333 and $488,335 per the terms
of
his Separation Agreement in 2006 and 2005,
respectively.
|
(7)
|
Phillip
S. Wise became Access’ Vice President Business Development June 1,
2006.
|
(8)
|
Jeffrey
B. Davis became Access’ Chief Executive Officer on December 26, 2007 and
is not included in this table. Stephen R. Seiler was Access’ President and
Chief Executive Officer effective January 4, 2007 through December
19,
2007 and is not included in this
table.
|
·
|
a
bonus payable in cash and Common Stock related to the attainment
of
reasonable performance goals specified by the
Board;
|
·
|
stock
options at the discretion of the
Board;
|
·
|
long-term
disability insurance to provide compensation equal to at least $60,000
annually; and
|
·
|
term
life insurance coverage of
$254,000.
|
·
|
a
bonus payable in cash and Common Stock related to the attainment
of
reasonable performance goals specified by the
Board;
|
·
|
stock
options at the discretion of the
Board;
|
·
|
long-term
disability insurance to provide compensation equal to at least $90,000
annually; and
|
·
|
term
life insurance coverage of
$155,000.
|
Payment
for shares purchased upon exercise of an option must be made in full
in
cash or check, by payment through a broker in accordance with Regulation
T
of the Federal Reserve Board or by such other mode of payment as
the
Committee may approve, including payment in whole or in part in shares
of
the Common Stock, when the option is exercised. No option is transferable
except by will or the laws of descent and distribution or pursuant
to a
qualified domestic relations order, as defined by the Code or in
Title I
of the Employee Retirement Income Security Act of 1974, as
amended.
|
Option
Awards
|
|||||
Name
|
Number
of Securities Underlying Unexercised Options (#)
Exercisable
|
Number
of Securities Underlying Unexercised Options (#)
Unexercisable
|
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised
Unearned Options (#)
|
Option
Exercise Price ($)
|
Option
Grant
Date
(5)
|
Rosemary
Mazanet(2)
(4)
|
50,000
39,796
6,000
|
150,000
10,204
|
-
|
0.63
5.45
12.50
|
08/17/06
11/02/05
05/11/05
|
Kerry
P. Gray(3)
|
20,000
28,000
32,000
32,000
20,000
100,000
32,000
32,000
|
-
|
29.25
11.50
18.65
34.38
27.50
12.50
10.00
15.00
|
01/23/04
05/19/03
03/22/02
11/20/00
10/12/00
03/01/00
07/20/99
06/18/98
|
|
David
P. Nowotnik, Ph.D.
|
25,000
3,167
3,646
6,854
10,000
10,000
10,000
10,000
|
75,000
4,833
1,354
146
|
-
|
0.63
11.60
29.25
10.10
18.65
12.50
10.00
15.00
|
08/17/06
05/23/05
01/23/04
01/30/03
03/22/02
03/01/00
07/20/99
11/16/98
|
Phillip
S. Wise
|
25,000
|
75,000
|
-
|
0.63
|
08/17/06
|
Stephen
B. Thompson
|
25,000
1,979
2,187
3,917
6,000
9,000
4,000
4,000
|
75,000
3,021
813
83
|
-
|
0.63
11.60
29.25
10.10
18.65
12.50
10.00
15.00
|
08/17/06
05/23/05
01/23/04
01/30/03
03/22/02
03/01/00
07/20/99
06/18/98
|
(1)
|
On
December 31, 2006, the closing price of Access’ Common Stock as quoted on
the OTC Bulletin Board was $2.80.
|
(2)
|
Options
listed for Dr. Mazanet include options paid to her in connection
with her
services as Access’ Acting CEO commencing on May 11,
2005.
|
(3)
|
Options
listed for Mr. Gray include options paid to him in connection with
his
services as Access’ President and CEO through May 10, 2005. Mr.
Gray resigned as CEO on May 10,
2005.
|
(4)
|
Jeffrey
B. Davis became Access’ Chief Executive Officer on December 26, 2007 and
is not included in this table. Stephen R. Seiler was Access’ President and
Chief Executive Officer effective January 4, 2007 through December
19,
2007 and is not included in this
table.
|
(5)
|
All
options expire 10 years after the grant
date.
|
Name
|
Fees
earned or Paid in Cash ($)
|
Option
Awards ($)(1)
|
All
Other Compensation ($)
|
Total
($)
|
Mark
J. Ahn, PhD (2)
|
4,000
|
7,592
|
-
|
11,592
|
Mark
J. Alvino (3)
|
13,000
|
5,581
|
-
|
18,581
|
Esteban
Cvitkovic, MD (8)
|
-
|
-
|
-
|
-
|
Jeffrey
B. Davis (3)
|
16,650
|
5,581
|
-
|
22,231
|
Stuart
M. Duty (4)
|
16,000
|
8,379
|
-
|
24,379
|
J.
Michael Flinn (5)
|
17,525
|
15,411
|
183,333
|
216,269
|
Stephen
B. Howell, MD (6)
|
12,000
|
6,137
|
-
|
18,137
|
David
P. Luci (8)
|
-
|
-
|
-
|
-
|
Rosemary
Mazanet, MD, PhD (9)
|
-
|
-
|
-
|
-
|
Max
Link, PhD (9)
|
12,000
|
556
|
-
|
12,557
|
Herbert
H. McDade, Jr. (6)
|
17,200
|
6,137
|
-
|
23,338
|
John
J. Meakem, Jr. (4)
|
16,000
|
8,379
|
-
|
24,380
|
|
(1)
|
|
The
value listed in the above table represents the fair value of the
options
recognized as expense under FAS 123R during 2006, including unvested
options granted before 2006 and those granted in 2006. Fair value
is
calculated as of the grant date using a Black-Scholes (“Black-Scholes”)
option-pricing model. The determination of the fair value of share-based
payment awards made on the date of grant is affected by Access’ stock
price as well as assumptions regarding a number of complex and subjective
variables. Access’ assumptions in determining fair value are described in
note 10 to Access’ audited financial statements for the year ended
December 31, 2006, included in Access’ Annual Report on Form
10-KSB.
|
(2)
|
Represents
expense recognized in 2006 in respect of option to purchase 25,000
shares
based on a grant date fair value of $7,592.
|
||
(3)
|
Represents
expense recognized in 2006 in respect of option to purchase 25,000
shares
based on grant date fair value of $5,581.
|
||
(4)
|
Represents
expense recognized in 2006 in respect of option to purchase 25,000
shares
based on a grant date fair value of $5,581; option to purchase 1,200
shares based on a grant date fair value of $556; and option to
purchase 4,836 shares based on a grant date fair value of
$2,242.
|
||
(5)
|
Represents
expense recognized in 2006 in respect of option to purchase 25,000
shares
based on a grant date fair value of $5,581; option to purchase 1,200
shares based on a grant date fair value of $556; and option to
purchase 20,000 shares based on a grant date fair value of
$9,274.
|
||
(6)
|
Represents
expense recognized in 2006 in respect of option to purchase 25,000
shares
based on a grant date fair value of $5,581 and option to purchase
1,200
shares based on a grant date fair value of $556.
|
||
(7)
|
Represents
expense recognized in 2006 in respect of option to purchase 1,200
shares
based on grant date fair value of $556.
|
||
(8)
|
Dr.
Cvitkovic and Mr. Luci became directors in 2007.
|
||
(9)
|
Dr.
Mazanet was an inside director during 2006 and was not paid directors
fees. She became an outside director in January
2007.
|
Name
|
Number
of Securities Underlying Unexercised Options (#)
Exercisable
|
Number
of Securities Underlying Unexercised Options (#)
Unexercisable
|
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised
Unearned Options (#)
|
Option
Exercise Price ($)
|
Option
Expiration Date
|
Mark
J. Ahn, PhD
|
-
|
25,000
|
-
|
0.85
|
09/01/16
|
Mark
J. Alvino
|
-
|
25,000
|
-
|
0.63
|
08/17/16
|
Jeffrey
B. Davis
|
-
|
25,000
|
-
|
0.63
|
08/17/16
|
Esteban
Cvitkovic, MD (1)
|
-
|
-
|
-
|
-
|
-
|
Stuart
M. Duty
|
2,500
4,836
1,200
|
25,000
|
-
|
0.63
12.40
3.15
3.15
|
08/17/16
5/12/15
2/05/16
2/05/16
|
J.
Michael Flinn
|
2,000
2,000
1,000
2,000
2,000
2,500
2,500
2,500
1,200
20,000
|
25,000
|
-
|
0.63
15.00
10.00
17.81
23.05
14.05
11.50
28.50
12.40
3.15
3.15
|
08/17/16
06/18/08
07/20/09
06/26/10
05/21/11
05/20/12
05/19/13
05/19/14
05/12/15
02/05/16
02/05/16
|
Stephen
B. Howell, MD (3)
|
417
1,000
2,000
2,000
2,500
2,500
2,500
1,200
|
25,000
|
-
|
0.63
15.00
17.81
23.05
14.05
11.50
28.50
12.40
3.15
|
08/17/16
06/18/08
06/26/10
05/21/11
05/20/12
05/19/13
05/19/14
05/12/15
02/05/16
|
David
P. Luci (1)
|
-
|
-
|
-
|
-
|
-
|
Rosemary
Mazanet, MD, PhD (2)
|
-
|
||||
Max
Link, PhD
|
1,200
|
-
|
0.63
|
08/17/16
|
|
Herbert
H. McDade, Jr.
|
2,500
1,000
2,000
2,000
2,500
2,500
1,200
|
25,000
|
-
|
0.63
15.00
17.81
23.05
14.05
28.50
12.40
3.15
|
08/17/16
06/18/08
06/26/10
05/21/11
05/20/12
05/19/14
05/12/15
02/05/16
|
John
J. Meakem, Jr.
|
4,000
2,000
2,500
2,500
2,500
4,836
1,200
|
25,000
|
-
|
0.63
20.25
14.05
11.50
28.50
12.40
3.15
3.15
|
08/17/16
02/16/11
05/20/12
05/19/13
05/19/14
05/12/15
02/05/16
02/05/16
|
(1)
|
Dr.
Cvitkovic and Mr. Luci became directors in 2007.
|
(2)
|
Since
Dr. Mazanet became an outside director in January 2007, her options
are
reported in the executive compensation tables.
|
(3)
|
Dr.
Howell also has a warrant to purchase 3,000 shares of Access Common
Stock
at an exercise price of $15.00 per share, and a warrant to purchase
2,000
shares of Access Common Stock at an exercise price of $24.80 per
share.
|
Common
Stock Beneficially Owned
|
||
Name
of Beneficial Owner
|
Number
of Shares(1)
|
%
of Class
|
Steven
H. Rouhandeh(2)
|
-
|
*
|
Jeffery
B. Davis (3)
|
30,820
|
*
|
Mark
J. Ahn, Ph. D. (4)
|
25,000
|
*
|
Mark
J. Alvino (5)
|
80,525
|
1.4%
|
Esteban
Cvitkovic, M.D. (6)
|
50,000
|
*
|
Stephen
B. Howell, M.D. (7)
|
53,839
|
*
|
David
P. Luci (8)
|
37,500
|
*
|
Rosemary
Mazanet, M.D., Ph.D.(9)
|
279,251
|
4.7%
|
John
J. Meakem, Jr.
(10)
|
53,536
|
*
|
David
P. Nowotnik, Ph.D. (11)
|
175,349
|
3.0%
|
Phillip
S. Wise (12)
|
100,000
|
1.8%
|
Stephen
B. Thompson (13)
|
143,167
|
2.5%
|
SCO
Capital Partners LLC, SCO Capital Partners LP, and Beach Capital
LLC (14)
|
13,001,870
|
69.8%
|
Larry
N. Feinberg (15)
|
2,479,372
|
31.7%
|
Lake
End Capital LLC (16)
|
1,556,966
|
21.7%
|
Perceptive
Life Sciences
Master
Fund, Ltd. (17)
|
999,999
|
15.1%
|
Midsummer
Investment, Ltd. (18)
|
750,000
|
11.8%
|
All
Directors and Executive
Officers
as a group
(consisting
of 12 persons) (19)
|
1,028,987
|
15.6%
|
(1)
|
Includes
Access’ outstanding shares of Common Stock held plus all shares of Common
Stock issuable upon conversion of Series A Preferred Stock, exercise
of
options, warrants and other rights exercisable within 60 days of
March 6,
2008.
|
(2)
|
Steven
H. Rouhandeh is Chairman of SCO Securities LLC. a wholly-owned subsidiary
of SCO Financial Group LLC. His address is c/o SCO Capital Partners
LLC,
1285 Avenue of the Americas, 35th Floor, New York, NY 10019. SCO
Securities LLC and affiliates (SCO Capital Partners LP and Beach
Capital
LLC) are known to beneficially own warrants to purchase an aggregate
of
5,924,770 shares of Access’ Common Stock and 7,077,100 shares of Common
Stock are issuable to them upon conversion of Series A Preferred
Stock.
Mr. Rouhandeh disclaims beneficial ownership of all such shares except
to
the extent of his pecuniary interest
therein.
|
(3)
|
Includes
5,820 shares underlying warrants held directly by Mr. Davis and presently
exercisable options for the purchase of 25,000 shares of Access’ Common
Stock pursuant to the 2005 Equity Incentive Plan. Mr. Davis is President
of SCO Securities LLC, a wholly-owned subsidiary of SCO Financial
Group
LLC. His address is c/o SCO Capital Partners LLC, 1285 Avenue of
the
Americas, 35th Floor, New York, NY 10019. SCO Securities LLC and
affiliates (SCO Capital Partners LP and Beach Capital LLC) are known
to
beneficially own warrants to purchase an aggregate of 5,924,770 shares
of
Access’ Common Stock and 7,077,100 shares of Common Stock are issuable to
them upon conversion of Series A Preferred Stock. Mr. Davis disclaims
beneficial ownership of all such shares except to the extent of his
pecuniary interest therein.
|
(4)
|
Includes
presently exercisable options for the purchase of 25,000 shares of
Access’
Common Stock pursuant to the 2005 Equity Incentive
Plan.
|
(5)
|
Includes
55,525 shares of Common Stock underlying warrants held by Mr. Alvino
and
presently exercisable options for the purchase of 25,000 shares of
Access’
Common Stock pursuant to the 2005 Equity Incentive Plan. Mr. Alvino
is
Managing Director of Griffin Securities LLC. His address is c/o Griffin
Securities LLC, 17 State St., 3rd
Floor, New York, NY 10004. Mr. Alvino is a designated director of
SCO
Securities LLC. SCO Securities LLC and affiliates (SCO Capital Partners
LP
and Beach Capital LLC) are known to beneficially own warrants to
purchase
an aggregate of 5,924,770 shares of Access’ Common Stock and 7,077,100
shares of Common Stock are issuable to them upon conversion of Series
A
Preferred Stock. Mr. Alvino disclaims beneficial ownership of all
such
shares except to the extent of his pecuniary interest therein. Mr.
Alvino
disclaims beneficial ownership of all such shares except to the extent
of
his pecuniary interest therein.
|
(6)
|
Includes
presently exercisable options for the purchase of 50,000 shares of
Access’
Common Stock pursuant to the 2005 Equity Incentive
Plan.
|
(7)
|
Includes
presently exercisable options for the purchase of 26,200 shares of
Access’
Common Stock pursuant to the 2005 Equity Incentive Plan, 12,917 shares
of
Access’ Common Stock pursuant to the 1995 Stock Option Plan, a warrant to
purchase 3,000 shares of Access’ Common Stock at an exercise price of
$15.00 per share, and a warrant to purchase 2,000 shares of Access’ Common
Stock at an exercise price of $24.80 per
share.
|
(8)
|
Includes
warrants to purchase an aggregate of 4,167 shares of Access’ Common Stock,
8,333 shares of Common Stock are issuable to him upon conversion
of Series
A Preferred Stock and presently exercisable options for the purchase
of
25,000 shares of Access’ Common Stock pursuant to the 2005 Equity
Incentive Plan.
|
(9)
|
Includes
presently exercisable options for the purchase of 273,251 shares
of
Access’ Common Stock pursuant to the 2005 Equity Incentive Plan and 6,000
shares of Access’ Common Stock pursuant to the 1995 Stock Option
Plan.
|
(10)
|
Includes
presently exercisable options for the purchase of 31,036 shares of
Access’
Common Stock pursuant to the 2005 Equity Incentive Plan and 13,500
shares
of Access’ Common Stock pursuant to the 1995 Stock Option
Plan.
|
(11)
|
Includes
presently exercisable options for the purchase of 100,000 shares
of
Access’ Common Stock pursuant to the 2005 Equity Incentive Plan and 57,833
shares of Access’ Common Stock pursuant to the 1995 Stock Option
Plan.
|
(12)
|
Includes
presently exercisable options for the purchase of 100,000 shares
of
Access’ Common Stock pursuant to the 2005 Equity Incentive
Plan.
|
(13)
|
Includes
presently exercisable options for the purchase of 100,000 shares
of
Access’ Common Stock pursuant to the 2005 Equity Incentive Plan and 33,646
shares of Access’ Common Stock pursuant to the 1995 Stock Option
Plan.
|
(14)
|
SCO
Capital Partners LLC, SCO Capital Partner LP and Beach Capital LLC's
address is 1285 Avenue of the Americas, 35th
Floor, New York, NY 10019. SCO Capital Partners LLC and affiliates
(SCO
Capital Partners LP and Beach Capital LLC) are known to beneficially
own
warrants to purchase an aggregate of 5,924,770 shares of Access’ Common
Stock and 7,077,100 shares of Common Stock issuable to them upon
conversion of Series A Preferred Stock. Each of Mr. Rouhandeh. Mr.
Davis
and Mr. Alvino, Access’ directors and Mr. Rouhandeh and Mr. Davis a
executives with SCO Capital Partners LLC, disclaim beneficial ownership
of
such shares except to the extent of their pecuniary interest
therein.
|
(15)
|
Larry
N. Feinberg is a partner in Oracle Partners, L.P. His address is
c/o
Oracle Partners, L.P., 200 Greenwich Avenue, 3rd
Floor, Greenwich, CT 06830. Oracle Partners, L.P. and affiliates
(Oracle
Institutional Partners, L.P., Oracle Investment Management, Inc.,
Sam
Oracle Fund, Inc. and Mr. Feinberg) are known to beneficially own
an
aggregate of 339,964 shares of Access’ Common Stock, warrants to purchase
an aggregate of 728,850 shares of Access’ Common Stock and Series A
Preferred Stock which may be converted into an aggregate of 1,457,699
shares of Access’ Common Stock.
|
(16)
|
Lake
End Capital LLC’s address is 1285 Avenue of the Americas, 35th
Floor, New York, NY 10019. Lake End Capital LLC is known to beneficially
own warrants to purchase an aggregate of 1,195,717 shares of Access’
Common Stock and 793,067 shares of Common Stock issuable to them
upon
conversion of Series A Preferred
Stock.
|
(17)
|
Perceptive
Life Sciences Master Fund, Ltd.’s address is 499 Park Ave., 25th
Fl., New York, NY 10022. Perceptive Life Sciences Master Fund is
known to
beneficially own warrants to purchase an aggregate of 333,333 shares
of
Access’ Common Stock and Series A Preferred Stock which may be converted
into an aggregate of 666,666 shares of Access’ Common
Stock.
|
(18)
|
Midsummer
Investment, Ltd.’s address is 295 Madison Ave., 38th
Fl., New York, NY 10017. Midsummer Investment is known to beneficially
own
warrants to purchase an aggregate of 250,000 shares of Access’ Common
Stock and Series A Preferred Stock which may be converted into an
aggregate of 500,000 shares of Access’ Common
Stock.
|
(19)
|
Does
not include shares held by SCO Securities LLC and
affiliates.
|
Plan
Categorty
|
Number
of securities to be issued upon exercise of outstanding options,
warrants and rights
|
Weighted-average
exercise price of outstanding options, warrants and rights
|
Number
of securities remaining available for future issuance under equity
compensation plans (excluding securities reflected in column (a))
|
(a)
|
(b)
|
(c)
|
|
Equity
compensation plans approved by security holders
|
|||
2005
Equity Incentive Plan
1995
Stock Awards Plan
2001
Restricted Stock Plan
|
802,672
360,917
-
|
$ 1.04
$18.03
-
|
197,328
-
52,818
|
Equity
compensation plans not approved by security holders
|
|||
2000
Special Stock
Option
Plan *
|
100,000
|
$12.50
|
-
|
Total
|
1,263,589
|
$
6.80
|
250,146
|
Common
Stock
|
|
||||||||
High
|
Low
|
||||||||
Period
Ended
|
|||||||||
First
quarter March 7, 2008
|
$ | 3.60 | $ | 1.90 | |||||
Fiscal
Year Ended December 31,
2007
|
|||||||||
First
quarter
|
$ | 10.66 | $ | 2.50 | |||||
Second
quarter
|
6.75 | 4.30 | |||||||
Third
quarter
|
5.16 | 2.10 | |||||||
Fourth
quarter
|
4.48 | 2.10 | |||||||
Fiscal
Year Ended December 31,
2006
|
|||||||||
First
quarter
|
$ | 2.65 | $ | 0.80 | |||||
Second
quarter
|
1.50 | 0.10 | |||||||
Third
quarter
|
1.30 | 0.45 | |||||||
Fourth
quarter
|
3.00 | 1.05 | |||||||
PAGE
|
|
Report
of Independent Registered Public Accounting
Firm
|
F-2
|
Consolidated
Balance Sheets at December 31, 2006 and 2005
|
F-3
|
Consolidated
Statements of Operations and Comprehensive Loss for 2006, 2005 and
2004
|
F-4
|
Consolidated
Statement of Stockholders' Equity (Deficit) for 2006, 2005 and
2004
|
F-5
|
Consolidated
Statements of Cash Flows for 2006, 2005 and
2004
|
F-6
|
Notes
to Consolidated Financial Statements (Three years ended December
31,
2006)
|
F-7
|
Condensed
Consolidated Balance Sheets at September 30, 2007
(unaudited)
|
F-24
|
Condensed
Consolidated Statements of Operations for September 30, 2007 and
2006
(unaudited)
|
F-25
|
Condensed
Consolidated Statements of Cash Flows for September 30, 2007 and
2006
(unaudited)
|
F-26
|
Notes
to Condensed Consolidated Financial Statements (Nine Months Ended
September 30, 2007 and 2006) (unaudited)
|
F-27
|
ASSETS
|
December
31, 2006
|
December
31, 2005
|
|||||
Current
assets
|
|||||||
Cash
and cash equivalents
|
$
|
1,194,000
|
$
|
349,000
|
|||
Short
term investments, at cost
|
3,195,000
|
125,000
|
|||||
Receivables
|
359,000
|
4,488,000
|
|||||
Prepaid
expenses and other current assets
|
283,000
|
197,000
|
|||||
Total
current assets
|
5,031,000
|
5,159,000
|
|||||
Property
and equipment, net
|
212,000
|
300,000
|
|||||
Debt
issuance costs, net
|
158,000
|
-
|
|||||
Patents,
net
|
878,000
|
1,046,000
|
|||||
Licenses,
ne
|
25,000
|
75,000
|
|||||
Restricted
cash and other assets
|
122,000
|
633,000
|
|||||
Total
assets
|
$
|
6,426,000
|
$
|
7,213,000
|
|||
LIABILITIES
AND STOCKHOLDERS' DEFICIT
|
|||||||
Current
liabilities
|
|||||||
Accounts
payable and accrued expenses
|
$
|
1,226,000
|
$
|
2,883,000
|
|||
Accrued
interest payable
|
581,000
|
652,000
|
|||||
Deferred
revenues
|
173,000
|
173,000
|
|||||
Current
portion long-term debt, net
of discount $2,062,000 in 2006
|
8,833,000
|
106,000
|
|||||
Total
current liabilities
|
10,813,000
|
3,814,000
|
|||||
Long-term
debt, net of discount $1,879,000 in 2005
|
5,500,000
|
7,636,000
|
|||||
Total
liabilities
|
16,313,000
|
11,450,000
|
|||||
Commitments
and contingencies
|
|||||||
Stockholders'
deficit
|
|||||||
Preferred
stock - $.01 par value; authorized 2,000,000 shares;
none
issued or outstanding
|
-
|
-
|
|||||
Common
stock - $.01 par value; authorized 100,000,000 shares;
issued,
3,535,108 at December 31, 2006 and authorized
50,000,000
shares; issued 3,528,108 at December 31, 2005
|
35,000
|
35,000
|
|||||
Additional
paid-in capital
|
68,799,000
|
62,942,000
|
|||||
Notes
receivable from stockholders
|
(1,045,000
|
)
|
(1,045,000
|
)
|
|||
Treasury
stock, at cost - 163 shares
|
(4,000
|
)
|
(4,000
|
)
|
|||
Accumulated
deficit
|
(77,672,000
|
)
|
(66,165,000
|
)
|
|||
Total
stockholders' deficit
|
(9,887,000
|
)
|
(4,237,000
|
)
|
|||
Total
liabilities and stockholders' deficit
|
$
|
6,426,000
|
$
|
7,213,000
|
Year
ended December 31,
|
||||||||||
2006
|
2005
|
2004
|
||||||||
Expenses
|
||||||||||
Research
and development
|
$
|
2,053,000
|
$
|
2,783,000
|
$
|
2,335,000
|
||||
General
and administrative
|
2,813,000
|
4,638,000
|
3,199,000
|
|||||||
Depreciation
and amortization
|
309,000
|
333,000
|
469,000
|
|||||||
Write
off of goodwill
|
-
|
1,868,000
|
-
|
|||||||
Total
expenses
|
5,175,000
|
9,622,000
|
6,003,000
|
|||||||
Loss
from operations
|
(5,175,000
|
)
|
(9,622,000
|
)
|
(6,003,000
|
)
|
||||
Interest
and miscellaneous income
|
294,000
|
100,000
|
226,000
|
|||||||
Interest
and other expense
|
(7,436,000
|
)
|
(2,100,000
|
)
|
(1,385,000
|
)
|
||||
Unrealized
loss on fair value of warrants and beneficial
conversion
feature
|
(1,107,000
|
)
|
-
|
-
|
||||||
(8,249,000
|
)
|
(2,000,000
|
)
|
(1,159,000
|
||||||
Loss
before discontinued operations and before tax benefit
|
(13,424,000
|
)
|
(11,622,000
|
)
|
(7,162,000
|
)
|
||||
Income
tax benefit
|
173,000 |
4,067,000
|
-
|
|||||||
Loss
from continuing operations
|
(13,251,000
|
)
|
(7,555,000
|
)
|
(7,162,000
|
)
|
||||
Discontinued
operations, net of taxes of $173,000 in 2006 and $4,067,000
in
2005
|
377,000
|
5,855,000
|
(3,076,000
|
)
|
||||||
Net
loss
|
$
|
(12,874,000
|
)
|
$
|
(1,700,000
|
)
|
$
|
(10,238,000
|
)
|
|
Basic
and diluted loss per common share
|
||||||||||
Loss
from continuing operations allocable to common
stockholders
|
$
|
(3.75
|
)
|
$
|
(2.34
|
)
|
$
|
(2.36
|
)
|
|
Discontinued
operations
|
0.11
|
1.81
|
(1.02
|
)
|
||||||
Net
loss allocable to common stockholders
|
$
|
(3.65
|
)
|
$
|
(0.53
|
)
|
$
|
(3.38
|
)
|
|
Weighted
average basic and diluted common shares
outstanding
|
3,531,934
|
3,237,488
|
3,032,451
|
|||||||
Net
loss
|
$
|
(12,874,000
|
)
|
$
|
(
1,700,000
|
)
|
$
|
(10,238,000
|
)
|
|
Other
comprehensive loss
Foreign
currency translation adjustment
|
-
|
3,000
|
(17,000
|
)
|
||||||
Comprehensive
loss
|
$
|
(12,874,000
|
)
|
$
|
(1,697,000
|
)
|
$
|
(10,255,000
|
)
|
Common
Stock
|
|||||||||||||||||||||||
Shares
|
Amount
|
Additional
paid in capital
|
Notes
receivable from stockholders
|
Unamortized
value
of restricted stock grants
|
Treasury
stock
|
Accumulated
other
comprehensive
income
(loss)
|
Accumulated
deficit
|
||||||||||||||||
Balance,
December 31, 2003
|
2,679,000
|
$
27,000
|
$49,704,000
|
(1,045,000)
|
$(294,000)
|
$(4,000)
|
$14,000
|
$(54,227,000)
|
|||||||||||||||
Common
stock issued
for
cash, net of offering
costs
|
359,000
|
4,000
|
9,012,000
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Common
stock issued for
cash
exercise of
warrants
and options
|
23,000
|
-
|
283,000
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Common
stock issued for cashless
exercise
of warrants
|
42,000
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Issuance
of restricted
stock
grants
|
2,000
|
-
|
135,000
|
-
|
(135,000)
|
-
|
-
|
-
|
|||||||||||||||
Other
comprehensive
loss
|
-
|
-
|
-
|
-
|
-
|
-
|
(17,000)
|
-
|
|||||||||||||||
Amortization
of restricted stock grants
|
-
|
-
|
-
|
-
|
120,000
|
-
|
-
|
-
|
|||||||||||||||
Net
loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(10,238,000)
|
|||||||||||||||
Balance,
December 31, 2004
|
3,105,000
|
31,000
|
59,134
000
|
(1,045,000)
|
(309,000)
|
(4,000)
|
(3,000)
|
(64,465,000)
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||||
Common
stock issued,
net
of offering costs
|
237,000
|
2,000
|
1,119,000
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Common
stock issued
for
payment of interest
|
190,000
|
2,000
|
616,000
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Other
comprehensive
income
|
-
|
-
|
-
|
-
|
-
|
-
|
3,000
|
-
|
|||||||||||||||
Discount
on convertible
note
extension
|
-
|
-
|
2,109,000
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Amortization
and
forfeiture
of restricted
stock
grants
|
(4,000)
|
-
|
(36,000)
|
-
|
309,000
|
-
|
-
|
-
|
|||||||||||||||
Net
loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(1,700,000)
|
|||||||||||||||
Balance,
December 31, 2005
|
3,528,000
|
35,000
|
62,942,000
|
(1,045,000)
|
-
|
(4,000)
|
-
|
(66,165,000)
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||||
Common
stock issued for
compensation
|
7,000
|
-
|
77,000
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Warrants
issued
|
-
|
-
|
100,000
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Stock
option
compensation
expense
|
-
|
-
|
248,000
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Issuance
of convertible
debt
with warrants
|
-
|
-
|
5,432,000
|
-
|
-
|
-
|
-
|
-
|
|||||||||||||||
Cumulative
effect of
change
in accounting
principle
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1,367,000
|
|||||||||||||||
Net
loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(12,874,000)
|
|||||||||||||||
Balance,
December 31, 2006
|
3,535,000
|
$
35,000
|
$
68,799,000
|
(1,045,000)
|
$
-
|
$
(4,000)
|
$
-
|
$(77,672,000)
|
Year
ended December 31,
|
||||||||||
2006
|
2005
|
2004
|
||||||||
Cash
flows from operating activities
|
||||||||||
Net
loss
|
$
|
(12,874,000
|
)
|
$
|
(1,700,000
|
)
|
$
|
(10,238,000
|
)
|
|
Adjustments
to reconcile net loss to net cash used
|
||||||||||
in
operating activities:
|
||||||||||
Unrealized
Loss
|
1,107,000
|
-
|
-
|
|||||||
Loss
on sale Australia assets
|
-
|
208,000
|
-
|
|||||||
Impairment
of investment
|
-
|
-
|
112,000
|
|||||||
Write
off of goodwill
|
-
|
1,868,000
|
-
|
|||||||
Amortization
of restricted stock grants
|
-
|
309,000
|
120,000
|
|||||||
Stock
option expense
|
248,000
|
-
|
-
|
|||||||
Stock
issued for compensation
|
77,000
|
42,000
|
-
|
|||||||
Stock
issued for interest
|
-
|
618,000
|
-
|
|||||||
Depreciation
and amortization
|
309,000
|
570,000
|
773,000
|
|||||||
Amortization
of debt costs and discounts
|
6,749,
000
|
695,000
|
183,000
|
|||||||
Gain
on sale of assets
|
(550,000)
|
(12,891,000
|
)
|
-
|
||||||
Change
in operating assets and liabilities:
|
||||||||||
Receivables
|
4,129,000
|
622,000
|
358,000
|
|||||||
Inventory
|
-
|
104,000
|
60,000
|
|||||||
Prepaid
expenses and other current assets
|
14,000
|
|
817,000
|
(195,000
|
)
|
|||||
Restricted
cash and other assets
|
127,000
|
-
|
-
|
|||||||
Accounts
payable and accrued expenses
|
(1,657,000
|
)
|
490,000
|
401,000
|
||||||
Accrued
interest payable
|
363,000
|
341,000
|
-
|
|||||||
Deferred
revenues
|
-
|
606,000
|
15,000
|
|||||||
Net
cash used in operating activities
|
(1,958,000
|
)
|
(7,301,000
|
)
|
(8,411,000
|
)
|
||||
Cash
flows from investing activities:
|
||||||||||
Capital
expenditures
|
(3,000
|
)
|
(28,000
|
)
|
(221,000
|
)
|
||||
Proceeds
from sale of equipment
|
-
|
355,000
|
-
|
|||||||
Proceeds
from sale of patents
|
-
|
974,000
|
-
|
|||||||
Proceeds
from sale of oral/topical care assets
|
550,000
|
7,391,000
|
-
|
|||||||
Restricted
cash and other assets
|
|
684,000
|
(666,000
|
)
|
||||||
Redemptions
of short-term investments
|
||||||||||
and
certificates of deposit, net
|
(3,070,000
|
)
|
361,000
|
1,374,000
|
||||||
Net
cash provided by (used in) investing activities
|
(2,523,000
|
)
|
9,717,000
|
487,000
|
||||||
Cash
flows from financing activities:
|
||||||||||
Payments
of notes payable
|
(106,000
|
)
|
(407,000
|
)
|
(310,000
|
)
|
||||
Payment
of secured notes payable and convertible notes
|
-
|
(6,648,000
|
)
|
-
|
||||||
Proceeds
from secured notes payable
|
5,432,000
|
2,633,000
|
-
|
|||||||
Proceeds
from stock issuances, net of costs
|
-
|
577,000
|
9,299,000
|
|||||||
Net
cash provided by (used in) financing activities
|
5,326,000
|
(3,845,000
|
)
|
8,989,000
|
||||||
Net
increase (decrease) in cash and cash equivalents
|
845,000
|
(1,429,000
|
)
|
1,065,000
|
||||||
Effect
of exchange rate changes on cash and cash equivalents
|
-
|
3,000
|
(17,000
|
)
|
||||||
Cash
and cash equivalents at beginning of year
|
349,000
|
1,775,000
|
727,000
|
|||||||
Cash
and cash equivalents at end of year
|
$
|
1,194,000
|
$
|
349,000
|
$
|
1,775,000
|
||||
Cash
paid for
interest
|
$
|
315,000
|
$
|
445,000
|
$
|
1,073,000
|
||||
Supplemental
disclosure of
noncash transactions
|
||||||||||
Value
of restricted stock
grants
|
-
|
-
|
135,000
|
|||||||
Assets
acquired under capital
leases
|
-
|
-
|
59,000
|
|||||||
Common
stock issued for SEDA
and
|
||||||||||
Secured
Convertible
Notes
|
-
|
502,000
|
-
|
|||||||
Discount
on convertible note
extension
|
-
|
2,109,000
|
-
|
|||||||
Debt
issuance
costs
|
568,000
|
|||||||||
Accrued
interest
capitalized
|
433,000
|
|||||||||
Warrants
issued per
professional agreement of consulting services
|
100,000
|
|||||||||
Cumulative
change of
accounting principle
|
1,367,000
|
|||||||||
Issuance
of convertible debt
with warrants
|
5,432,000
|
December
31, 2006
|
December
31, 2005
|
December
31, 2004
|
|||||||||||||||||
Gross
carrying
value
|
Accumulated
amortization
|
Gross
carrying
value
|
Accumulated
amortization
|
Gross
carrying
value
|
Accumulated
amortization
|
||||||||||||||
Amortizable
intangible assets
|
|||||||||||||||||||
Patents
|
$
|
1,680
|
$
|
802
|
$
|
1,680
|
$
|
634
|
$
|
3,179
|
$
|
864
|
|||||||
Licenses
|
500
|
475
|
500
|
425
|
500
|
375
|
|||||||||||||
Total
|
$
|
2,180
|
$
|
1,277
|
$
|
2,180
|
$
|
1,059
|
$
|
3,679
|
$
|
1,239
|
2007
|
$
|
193
|
||
2008
|
168
|
|||
2009
|
168
|
|||
2010
|
168
|
|||
2011
|
168
|
|||
Thereafter
|
38
|
|||
Total
|
$
|
903
|
· |
127%
- the expected volatility assumption was based upon a combination
of
historical stock price volatility measured on a twice a month basis
and is
a reasonable indicator of expected volatility.
|
· |
4.85%
(average) - the risk-free interest rate assumption is based upon
U.S.
Treasury bond interest rates appropriate for the term of the Company’s
employee stock options.
|
· |
None
- the dividend yield assumption is based on our history and expectation
of
dividend payments.
|
· |
1.6
years - the estimated expected term (average of 1.6 years) is based
on
employee exercise behavior.
|
|
|
Year ended
December 31,
2006
|
|
Research
and development
|
|
$
|
68
|
General
and administrative
|
|
|
180
|
|
|
|
|
Stock-based
compensation expense included in operating expenses
|
|
|
248
|
|
|
|
|
Total
stock-based compensation expense
|
|
|
248
|
Tax
benefit
|
|
|
—
|
|
|
|
|
Stock-based
compensation expense, net of tax
|
|
$
|
248
|
|
|
|
(in
thousands)
|
Year
ended
December
31,
|
||||||
2006
|
|
|
2005
|
|
|||
Net
loss, as reported under APB 25 for the prior period (1)
|
$
|
N/A
|
$
|
(1,700
|
)
|
||
Add
back stock based employee compensation expense in
reported
net loss, net of related tax effects
|
-
|
-
|
|||||
Subtract
total stock-based compensation expense determined
under
fair value-based method for all awards, net of related tax
effects(2)
|
(248
|
)
|
(750
|
)
|
|||
Net
loss including the effect of stock-based compensation expense(3)
|
$
|
(12,874
|
)
|
$
|
(2,450
|
)
|
|
Loss
per share:
|
|||||||
Basic
and diluted, as reported for the prior period(1)
|
$
|
(3.65
|
)
|
$
|
(0.53
|
)
|
|
Basic
and diluted, including the effect of stock-based
compensation
expense(3)
|
$
|
(3.65
|
)
|
$
|
(0.76
|
)
|
(1)
|
Net
loss and loss per share for periods prior to year 2006 does not
include
stock-based compensation expense under SFAS 123 because the Company
did
not adopt the recognition provisions of SFAS 123.
|
(2)
|
Stock-based
compensation expense for periods prior to year 2006 was calculated
based
on the pro forma application of SFAS 123.
|
(3)
|
Net
loss and loss per share for periods prior to year 2006 represent
pro forma
information based on SFAS 123.
|
Year
|
Consulting
Fees
|
Expense
Reimbursement
|
|||||
2006
|
$
|
69,000
|
$
|
5,000
|
|||
2005
|
79,000
|
5,000
|
|||||
2004
|
58,000
|
9,000
|
Property
and equipment consists of the following:
|
December
31,
|
||||||
2006
|
|
|
2005
|
||||
Laboratory
equipment
|
$
|
1,090,000
|
$
|
1,090,000
|
|||
Laboratory
and building improvements
|
167,000
|
167,000
|
|||||
Furniture
and equipment
|
134,000
|
138,000
|
|||||
|
1,391,000
|
1,395,000
|
|||||
Less
accumulated depreciation and amortization
|
1,179,000
|
1,095,000
|
|||||
Net
property and equipment
|
$
|
212,000
|
$
|
300,000
|
2006
|
2005
|
2004
|
||||||||
Revenues |
$
|
550,000
|
$
|
781,000
|
$
|
549,000
|
||||
|
||||||||||
Expenses | ||||||||||
Cost
of
product sales
|
|
(1,012,000
|
)
|
(239,000
|
)
|
|||||
Research
and
development
|
(2,501,000
|
)
|
(3,082,000
|
)
|
||||||
Depreciation
|
(237,000
|
)
|
(304,000
|
)
|
||||||
Total
expenses
|
-
|
(3,750,000
|
)
|
(3,625,000
|
)
|
|||||
|
||||||||||
Income/loss from discontinued operations |
550,000
|
(2,969,000
|
)
|
(3,076,000
|
)
|
|||||
|
||||||||||
Gain on sale of assets |
-
|
12,891,000
|
-
|
|||||||
Tax expense
|
(173,000
|
)
|
(4,067,000
|
)
|
-
|
|||||
Discontinued operations
|
$
|
377,000
|
$
|
5,855,000
|
$
|
(3,076,000
|
)
|
Future
Maturities
|
Debt
|
|
2007
|
10,895,000
|
|
2010
|
5,500,000
|
Summary of Warrants |
|
Outstanding
|
Exercise
Price
|
Expiration
Date
|
||||||||
2006
convertible note (a)
|
3,863,634
|
$
|
1.32
|
2/16/12
|
||||||||
2006
convertible note (a)
|
386,364
|
1.32
|
10/24/12
|
|||||||||
2006
convertible note (a)
|
386,364
|
1.32
|
12/06/12
|
|||||||||
2006
investor relations advisor (b)
|
50,000
|
2.70
|
12/27/11
|
|||||||||
2004
offering (c)
|
89,461
|
35.50
|
2/24/09
|
|||||||||
2004
offering (c)
|
31,295
|
27.00
|
2/24/09
|
|||||||||
2003
financial advisor (d)
|
14,399
|
19.50
|
10/30/08
|
|||||||||
2002
scientific consultant (e)
|
2,000
|
24.80
|
2/01/09
|
|||||||||
2001
scientific consultant (f)
|
3,000
|
15.00
|
1/1/08
|
|||||||||
Total
|
4,826,517
|
a) |
In
connection with the convertible note offerings in 2006, warrants
to
purchase a total of 4,636,362 shares of common stock were issued.
All of
the warrants are exercisable immediately and expire six years from
date of
issue.
|
b) |
During
2006, an investor relations advisor received warrants to purchase
50,000
shares of common stock at an exercise price of $2.70 per share
at any time
from December 27, 2006 until December 27, 2011, for investor relations
consulting services to be rendered in 2007. All of the warrants
were
exercisable at December 31, 2006. The fair value of the warrants
was $2.00
per share on the date of the grant using the Black-Scholes pricing
model
with the following assumptions: expected dividend yield 0.0%, risk-free
interest rate 4.58%, expected volatility 138% and a term of 2.5
years.
|
c) |
In
connection with offering of common stock in 2004, warrants to purchase
a
total of 120,756 shares of common stock were issued. All of the
warrants
are exercisable and expire five years from date of
issuance.
|
d) |
During
2003, financial advisors received warrants to purchase 14,399 shares
of
common stock at any time until October 30, 2008, for financial
consulting
services rendered in 2003 and 2004. All the warrants are exercisable.
The
fair value of the warrants was $14.10 per share on the date of
the grant
using the Black-Scholes pricing model with the following assumptions:
expected dividend yield 0.0%, risk-free interest rate 2.9%, expected
volatility 92% and a term of 5 years.
|
e) |
During
2002, a director who is also a scientific advisor received warrants
to
purchase 2,000 shares of common stock at an exercise price of $24.55
per
share at any time until February 1, 2009, for scientific consulting
services rendered in 2002. The fair value of the warrants was $18.50
per
share on the date of the grant using the Black-Scholes pricing
model with
the following assumptions: expected dividend yield 0.0%, risk-free
interest rate 3.90%, expected volatility 81% and a term of 7 years.
|
f) |
During
2001, a director who is also a scientific advisor received warrants
to
purchase 3,000 shares of common stock at an exercise price of $15.00
per
share at any time until January 1, 2008, for scientific consulting
services rendered in 2001. The fair value of the warrants was $13.70
per
share on the date of the grant using the Black-Scholes pricing
model with
the following assumptions: expected dividend yield 0.0%, risk-free
interest rate 5.03%, expected volatility 118% and a term of 7 years.
|
Weighted-
|
|||
average
|
|||
exercise
|
|||
Options
|
price
|
||
Outstanding
options at January 1, 2005
|
-
|
$
-
|
|
Granted,
fair value of $8.50 per share
|
50,000
|
5.45
|
|
Outstanding
options at December 31, 2005
|
50,000
|
5.45
|
|
Granted,
fair value of $ 0.36 per share
|
753,872
|
1.32
|
|
Forfeited
|
(1,200)
|
3.15
|
|
Outstanding
options at December 31, 2006
|
802,672
|
1.04
|
|
Exercisable
at December 31, 2005
|
14,000
|
5.45
|
|
Exercisable
at December 31, 2006
|
204,718
|
2.00
|
Number
of
|
Weighted
average
|
Number
of
|
Weighted
aververage
|
|||
|
options
|
Remaining
|
Exercise
|
options
|
Remaining
|
Exercise
|
Range
of excercise prices
|
outstanding
|
life
in years
|
price
|
exerciseable
|
life
in years
|
price
|
$0.63
- 0.85
|
717,000
|
9.6
|
$0.63
|
129,250
|
9.6
|
$0.63
|
$3.15
- 5.45
|
85,672
|
8.9
|
4.49
|
75,468
|
8.9
|
4.36
|
802,672
|
204,718
|
Weighted-
|
||
average
|
||
exercise
|
||
Options
|
price
|
|
Outstanding
options at January 1, 2004
|
410,725
|
$
17.25
|
Granted,
fair value of $10.90 per share
|
62,840
|
28.75
|
Exercised
|
(21,939)
|
11.90
|
Forfeited
|
(15,196)
|
21.05
|
Outstanding
options at December 31, 2004
|
436,430
|
18.80
|
Granted,
fair value of $6.45 per share
|
49,700
|
12.05
|
Forfeited
|
(55,859)
|
17.30
|
Outstanding
options at December 31, 2005
|
430,271
|
18.20
|
Forfeited
|
(69,354)
|
19.12
|
Outstanding
options at December 31, 2006
|
360,917
|
18.03
|
Exercisable
at December 31, 2004
|
334,232
|
18.20
|
Exercisable
at December 31, 2005
|
406,760
|
18.40
|
Exercisable
at December 31, 2006
|
349,990
|
18.12
|
Range
of
|
Number
of
|
Weighted
average
|
Number
of
|
Weighted
average
|
||
exercise
|
shares
|
Remaining
|
Exercise
|
shares
|
Remaining
|
Exercise
|
prices
|
outstanding
|
life
in years
|
price
|
exercisable
|
life
in years
|
Price
|
$10.00
- 12.50
|
147,640
|
3.6
|
$11.15
|
139,032
|
3.3
|
$11.12
|
$14.05
- 18.65
|
112,717
|
1.9
|
16.61
|
112,717
|
1.9
|
16.61
|
$20.25
- 34.38
|
100,560
|
2.1
|
29.73
|
98,241
|
2.0
|
29.74
|
|
|
|
|
|
|
|
|
360,917
|
|
|
349,990
|
|
|
2006
|
2005
|
2004
|
||||||||
Income
taxes at U.S. statutory rate
|
$
|
(4,378,000
|
)
|
$
|
(438,000
|
)
|
$
|
(3,442,000
|
)
|
|
Change
in valuation allowance
|
3,972,000
|
(2,051,000
|
)
|
895,000
|
||||||
Change
in miscellaneous items
|
(130,000) |
397,000
|
598,000
|
|||||||
Benefit
of foreign losses not recognized
|
58,000 |
304,000
|
-
|
|||||||
Expenses
not deductible
|
240,000 |
738,000
|
7,000
|
|||||||
Expiration
of net operating loss and general
|
||||||||||
business
credit carryforwards, net of revisions
|
238,000
|
1,050,000
|
1,942,000
|
|||||||
Total
tax expense
|
$
|
-
|
$
|
-
|
$
|
-
|
||||
December
31,
|
||||||||||
2006
|
2005
|
2004
|
||||||||
Deferred
tax assets (liabilities)
|
||||||||||
Net
operating loss carryforwards
|
$
22,634,000
|
$
20,261,000
|
$
20,808,000
|
|||||||
General
business credit carryforwards
|
2,402,000
|
2,261,000
|
2,094,000
|
|||||||
Deferred
gain on sale of oral/topical care assets
|
-
|
(1,490,000
|
)
|
-
|
||||||
Property,
equipment and goodwill
|
46,000
|
78,000
|
259,000
|
|||||||
Gross
deferred tax assets
|
25,082,000
|
21,110,000
|
23,161,000
|
|||||||
Valuation
allowance
|
(25,082,000
|
)
|
(21,110,000
|
)
|
(23,161,000
|
)
|
||||
Net
deferred taxes
|
$
|
-
|
$
|
-
|
$
|
-
|
||||
|
Net
operating
loss
carryforwards
|
General
business
credit
carryforwards
|
|||||
2007
|
$
|
994,000
|
$
|
26,000
|
|||
2008
|
4,004,000
|
138,000
|
|||||
2009
|
1,661,000
|
185,000
|
|||||
2010
|
2,171,000
|
140,000
|
|||||
2011
|
4,488,000
|
13,000
|
|||||
Thereafter
|
53,251,000
|
1,900,000
|
|||||
$
|
66,569,000
|
$
|
2,402,000
|
2006
Quarter Ended
|
|||||||||||||
March
31
|
June
30
|
September
30
|
December
31
|
||||||||||
Loss
from operations
|
$
|
(4,856
|
)
|
$
|
(3,331
|
)
|
$
|
(2,015
|
)
|
$
|
(3,222
|
)
|
|
Discontinued
operations
|
-
|
-
|
-
|
550
|
|||||||||
Net
loss
|
$
|
(4,856
|
)
|
$
|
(3,331
|
)
|
$
|
(2,015
|
)
|
$
|
(2,672
|
)
|
|
Basic
and diluted income/loss per common share
|
$
|
(1.38
|
)
|
$
|
(0.94
|
)
|
$
|
(0.57
|
)
|
$
|
(0.76
|
)
|
|
|
2005
Quarter Ended
|
||||||||||||
|
March
31
|
|
|
June
30
|
|
|
September30
|
|
|
December31
|
|||
Loss
from operations
|
$
|
(1,616
|
)
|
$
|
(2,988
|
)
|
$
|
(1,612
|
)
|
$
|
(1,339
|
)
|
|
Discontinued
operations
|
(806
|
)
|
(798
|
)
|
(451
|
)
|
7,910
|
||||||
Net
loss/income
|
$
|
(2,422
|
)
|
$
|
(3,786
|
)
|
$
|
(2,063
|
)
|
$
|
6,571
|
||
Basic
and diluted loss per
common
share
|
$
|
(0.78
|
)
|
$
|
(1.21
|
)
|
$
|
(0.65
|
)
|
$
|
2.11
|
|
September
30, 2007
|
December
31, 2006
|
|||||
ASSETS
|
(unaudited)
|
(audited)
|
|||||
Current
assets
Cash
and cash equivalents
Short
term investments, at cost
Receivables
Prepaid
expenses and other current assets
|
$
|
661,000
515,000
861,000
530,000
|
$
|
1,194,000
3,195,000
359,000
283,000
|
|||
Total
current assets
|
2,567,000
|
5,031,000
|
Property
and equipment, net
|
156,000
|
212,000
|
|||||
Debt
issuance costs, net
|
-
|
158,000
|
|||||
Patents,
net
|
752,000
|
878,000
|
|||||
Licenses,
net
|
-
|
25,000
|
|||||
Other
assets
|
25,000
|
122,000
|
|||||
Total
assets
|
$
|
3,500,000
|
$
|
6,426,000
|
|||
LIABILITIES
AND STOCKHOLDERS' DEFICIT
|
|||||||
Current
liabilities
Accounts
payable and accrued expenses
Accrued
interest payable
Deferred
revenues
Current
portion of long-term debt, net of discount $0 at
September
30, 2007 and $2,062,000 at December 31, 2006
|
$
|
1,595,000
1,023,000
1,167,000
11,406,000
|
$
|
1,226,000
581,000
173,000
8,833,000
|
|
||
Total
current liabilities
|
15,191,000
|
10,813,000
|
|||||
Long-term
debt
|
5,500,000
|
5,500,000
|
|||||
Total
liabilities
|
20,691,000
|
16,313,000
|
|||||
Commitments
and contingencies
|
-
|
-
|
|||||
Stockholders'
deficit
Preferred
stock - $.01 par value; authorized 2,000,000 shares;
none
issued or outstanding
Common
stock - $.01 par value; authorized 100,000,000 shares;
issued,
3,575,114 at September 30, 2007 and 3,535,108 at
December
31, 2006
Additional
paid-in capital
Notes
receivable from stockholders
Treasury
stock, at cost - 163 shares
Accumulated
deficit
|
-
36,000
69,687,000
(1,045,000
(4,000
(85,865,000
|
)
)
)
|
-
35,000
68,799,000
(1,045,000
(4,000
(77,672,000
|
)
)
)
|
|||
Total
stockholders' deficit
|
(17,191,000
|
)
|
(9,887,000
|
)
|
|||
Total
liabilities and stockholders' deficit
|
$
|
3,500,000
|
$
|
6,426,000
|
Three
months ended
|
Nine
months ended
|
||||||||||||
September
30,
|
September
30
|
||||||||||||
2007
|
2006
|
2007
|
2006
|
||||||||||
Revenues
|
License
revenues
|
$
|
6,000
|
$
|
-
|
$ | 6,000 |
$
|
-
|
|||||
Expenses
|
|||||||||||||
Research
and development
|
596,000
|
379,000
|
1,532,000 |
1,769,000
|
|||||||||
General
and administrative
|
1,000,000
|
800,000
|
3,252,000 |
2,129,000
|
|||||||||
Depreciation
and amortization
|
61,000
|
77,000
|
210,000 |
231,000
|
|||||||||
Total
expenses
|
1,657,000
|
1,256,000
|
4,994,000 |
4,129,000
|
|||||||||
Loss
from operations
|
(1,651,000
|
)
|
(1,256,000
|
)
|
(4,988,000 | ) |
(4,129,000
|
)
|
|||||
Interest
and miscellaneous income
|
12,000
|
86,000
|
72,000 |
278,000
|
|||||||||
Interest
and other expense
|
(318,000
|
)
|
(1,976,000
|
)
|
(3,277,000 | ) |
(5,244,000
|
)
|
Unrealized
gain (loss) on fair value of
warrants
and conversion feature
|
-
|
|
1,131,000
|
|
-
|
|
(1,107,000
|
)
|
|||||
(306,000
|
) |
(759,000
|
) | (3,205,000 | ) |
(6,073,000
|
) | ||||||
Net
loss
|
$
|
(1,957,000
|
)
|
$
|
(2,015,000
|
)
|
$
|
(8,193,000
|
)
|
$
|
(10,202,000
|
)
|
|
Basic
and diluted loss per common share
Net
loss allocable to common
shareholders
|
$
|
(0.55
|
)
|
$
|
(0.57
|
)
|
|
|
|
$
|
(2.89
|
)
|
|
Weighted
average basic and diluted
common
shares outstanding
|
3,575,114
|
3,534,408
|
3,544,181
|
3,530,941
|
Nine
months ended September 30,
|
|||||||
2007
|
2006
|
||||||
Cash
flows from operating activities:
|
|||||||
Net
loss
|
$
|
(8,193,000
|
)
|
$
|
(10,202,000
|
)
|
|
Adjustments
to reconcile net loss to cash used
in
operating activities:
|
|||||||
Depreciation
and amortization
|
210,000
|
230,000
|
|||||
Stock
option expense
|
810,000
|
171,000
|
|||||
Stock
compensation expense
|
-
|
69,000
|
|||||
Stock
issued for compensation
|
44,000
|
-
|
|||||
Amortization
of debt costs and discounts
|
2,316,000
|
4,192,000
|
|||||
Unrealized
loss on fair value of warrants and
conversion
feature
|
-
|
1,107,000
|
Loss on
sale of asset
|
2,000
|
|
-
|
||||
Change
in operating assets and liabilities:
|
|||||||
Receivables
|
(502,000
|
)
|
14,000
|
||||
Prepaid
expenses and other current assets
|
(247,000
|
)
|
143,000
|
||||
Other
assets
|
1,000
|
128,000
|
|||||
Accounts
payable and accrued expenses
|
369,000
|
(849,000
|
)
|
||||
Accrued
interest payable
|
953,000
|
805,000
|
|||||
Deferred
revenue
|
994,000
|
-
|
|||||
Net
cash used in operating activities
|
(3,243,000
|
)
|
(4,192,000
|
)
|
|||
Cash
flows from investing activities:
|
|||||||
Capital
expenditures
|
(18,000
|
)
|
(3,000
|
)
|
|||
Proceeds
from sale of asset
|
13,000
|
-
|
|||||
Redemptions
of short term investments and
certificates
of deposit, net
|
2,680,000
|
(98,000
|
)
|
||||
Net
cash provided by (used in) investing activities
|
2,675,000
|
(101,000
|
)
|
||||
Cash
flows from financing activities:
|
|||||||
Payments
of notes payable
|
-
|
(106,000
|
)
|
||||
Proceeds
from secured convertible notes payable
|
-
|
4,532,000
|
|||||
Exercise
of stock options
|
35,000
|
-
|
|||||
Net
cash provided by financing activities
|
35,000
|
4,426,000
|
|||||
Net
(decrease) increase in cash and cash equivalents
|
(533,000
|
)
|
133,000
|
||||
Cash
and cash equivalents at beginning of period
|
1,194,000
|
349,000
|
|||||
Cash
and cash equivalents at end of period
|
$
|
661,000
|
$
|
482,000
|
|||
Supplemental
cash flow
information:
|
|||||||
Cash
paid for
interest
|
$
|
5,000
|
$
|
5,000
|
|||
Accrued
interest
capitalized
|
511,000 | - |
(1) |
Interim
Financial
Statements
|
September
30,
2007
|
December
31,
2006
|
||||||||||||
Gross
carrying
value
|
Accumulated
amortization
|
Gross
carrying
value
|
Accumulated
amortization
|
||||||||||
Amortizable
intangible assets
Patents
Licenses
|
$
|
1,680
-
|
$
|
928
-
|
$
|
1,680
500
|
$
|
802
475
|
|||||
Total
|
$ | $1,680 |
$
|
928
|
$
|
2,180
|
$
|
1,277
|
2007 | $ | 42 | ||
2008 | 168 | |||
2009 | 168 | |||
2010 | 168 | |||
2011 | 168 | |||
Thereafter | 38 | |||
Total | $ | 752 |
|
|
9/30/07
|
|
|||
Expected
life
|
|
2.0
yrs.
|
|
|||
Risk
free interest rate
|
|
4.63
|
%
|
|||
Expected
volatility(a)
|
|
141
|
%
|
|||
Expected
dividend yield
|
|
0.0
|
%
|
|||
(a)
|
Reflects
movements in our stock price over the most recent historical period
equivalent to the expected life.
|
September
30,
2007
|
December
31,
2006
|
||||||
Convertible
note - Oracle and affiliates
|
$
|
4,015,000
|
$
|
4,015,000
|
|||
Convertible
note
|
5,500,000
|
5,500,000
|
|||||
Convertible
note
|
1,391,000
|
880,000
|
|||||
10,906,000
|
10,395,000
|
||||||
Discount
|
-
|
(456,000
|
)
|
||||
10,906,000
|
9,939,000
|
||||||
Convertible
note - SCO and affiliates
|
6,000,000
|
6,000,000
|
|||||
Discount
|
-
|
(1,606,000
|
)
|
||||
6,000,000
|
4,394,000
|
||||||
Total
|
$
|
16,906,000
|
$
|
14,333,000
|
|||
Short
term
|
$
|
11,406,000
|
$
|
8,833,000
|
|||
Long
term
|
5,500,000
|
5,500,000
|
|||||
Total
|
$
|
16,906,000
|
$
|
14,333,000
|
|||
Report
of Independent Registered Public Accounting Firm
|
F-32 |
Consolidated
Balance Sheet as of April 30, 2007
|
F-33 |
Consolidated
Statements of Operations for the years ended April 30, 2007 and
2006 and
for the period from inception of operations (April 19, 2001)
to April 30,
2007
|
F-34 |
Consolidated
Statements of Stockholders’ Deficit for the period from inception of
operations (April 19, 2001) to April 30, 2007
|
F-35 |
Consolidated
Statements of Cash Flows for the years ended April 30, 2007 and
2006 and
for the period from inception of operations (April 19, 2001)
to April 30,
2007
|
F-37
|
Notes
to Consolidated Financial Statements as of April 30, 2007
|
F-38 |
Condensed
Consolidated Balance Sheets at October 31, 2007
(unaudited)
|
F-63
|
Condensed
Consolidated Statements of Operations for the Three and Six
Months Ended
October 31, 2007 and 2006 and for the Period from Inception
of Operations
(April 19, 2001) to October 31, 2007 (unaudited)
|
F-64
|
Condensed
Consolidated Statement of Stockholders’ Deficit for the Period from
Inception of Operations (April 19, 2001) to October 31, 2007
(unaudited)
|
F-66
|
Condensed
Consolidated Statements of Cash Flows for the Six Months Ended
October 31,
2007 and 2006 and for the Period from Inception of Operations
(April 19,
2001) to October 31, 2007 (unaudited)
|
F-69
|
Notes
to Condensed Consolidated Financial Statements as of October
31,
2007
|
F-70
|
/s/ STONEFIELD
JOSEPHSON, INC.
|
|
Irvine,
California
|
|
June
27, 2007
|
Assets
|
||||
Current
assets:
|
||||
Cash
|
$
|
5,385
|
||
Prepaid
expenses
|
43,308
|
|||
Total
current assets
|
48,693
|
|||
Office
equipment,
net of accumulated depreciation of $6,750
|
16,560
|
|||
Other
assets:
|
||||
Restricted
funds
|
2,000
|
|||
Deposits
|
73
|
|||
Total
other assets
|
2,073
|
|||
Total
assets
|
$
|
67,326
|
||
Liabilities
and Stockholders’
Deficit
|
||||
Current
liabilities:
|
||||
Accounts
payable
|
$
|
774,022
|
||
Due
to related parties
|
241,874
|
|||
Accrued
expenses
|
811,539
|
|||
Accrued
research and development expenses
|
554,733
|
|||
Note
payable
|
33,462
|
|||
Liquidated
damages related to Series A preferred stock and warrants
|
35,200
|
|||
Deferred
revenue
|
7,143
|
|||
Warrant
liabilities
|
5,786,844
|
|||
Total
current liabilities
|
8,244,817
|
|||
Stockholders’
deficit:
|
||||
Preferred
stock,$0.001 par value, 20,000,000 shares authorized Series
A Convertible
Preferred Stock, $0.001 par value, 2,000 shares designated,
591.6318
shares issued and outstanding
|
1
|
|||
Common
Stock, $0.001 par value, 100,000,000 shares authorized, 14,292,603
shares
issued and outstanding
|
14,293
|
|||
Additional
paid-in capital
|
7,604,360
|
|||
Deficit
accumulated during the development stage
|
(15,796,145
|
)
|
||
Total
stockholders’ deficit
|
(8,177,491
|
)
|
||
Total
liabilities and
stockholders’ deficit
|
$
|
67,326
|
From
Inception
of
Operations(April
19,
2001)
to
April
30, 2007
|
||||||||||
Year
ended April
30,
|
||||||||||
2007
|
2006
|
|||||||||
Revenue
|
$
1,429
|
$
1,428
|
$
2,857
|
|||||||
Operating
expenses:
|
||||||||||
General
and
administrative
|
(3,312,660
|
) |
(2,845,634
|
) |
(7,337,118
|
) | ||||
Research
and
development
|
(1,239,146
|
)
|
(1,264,225
|
)
|
(3,100,647
|
)
|
||||
Loss
from
operations
|
(4,550,377
|
)
|
(4,108,431
|
)
|
(10,434,908
|
)
|
||||
Other
income
(expense):
|
||||||||||
Interest
income
|
28,084
|
12,348
|
40,432
|
|||||||
Interest
expense
|
(54
|
)
|
(1,016,020
|
)
|
(1,016,074
|
)
|
||||
Liquidated
damages
|
(35,200
|
)
|
—
|
(35,200
|
)
|
|||||
Change
in fair value of warrant
liabilities
|
(2,931,118
|
)
|
137,543
|
(2,793,575
|
)
|
|||||
Gain
on settlement of
debt
|
—
|
5,049
|
5,049
|
|||||||
Currency
translation
loss
|
(3,255
|
)
|
(30,241
|
)
|
(33,496
|
)
|
||||
Loss
before income
taxes
|
(7,491,920
|
)
|
(4,999,752
|
)
|
(14,267,772
|
)
|
||||
Income
taxes
|
(3,717
|
)
|
(2,339
|
)
|
(6,056
|
)
|
||||
Net
loss
|
(7,495,637
|
)
|
(5,002,091
|
)
|
(14,273,828
|
)
|
||||
Deemed
dividends on convertible
preferred stock
|
—
|
(1,522,317
|
)
|
(1,522,317
|
)
|
|||||
Net
loss applicable to common
shareholders
|
$
|
(7,495,637
|
)
|
$
|
(6,524,408
|
)
|
$
|
(15,796,145
|
)
|
|
Net
loss per share—basic and
diluted
|
$
|
(0.56
|
)
|
$
|
(0.47
|
)
|
$
|
(1.24
|
)
|
|
Weighted
average number of
shares outstanding—basic and diluted
|
14,278,247
|
14,274,365
|
13,247,052
|
|
|
Peferred Stock
|
Common Stock
|
Additional
Paid-in
|
Shares
to be
|
Subscription
|
Deferred
Equity-
Based
|
Accumulated
Other
Comprehensive
Loss-foreign
Currency
|
Deficit
Accumulated
During
Development
|
Total
Stockholders'
Equity/
|
||||||||||||||||||||||||
Shares
|
Amount |
Shares
|
Amount |
Capital
|
Issued
|
Receivable
|
Expense
|
Translation
|
Stage
|
(Deficit)
|
||||||||||||||||||||||||
Balance
at April 19, 2001(Inception)
|
|
-
|
$
-
|
|
$
-
|
$
-
|
$
-
|
$
-
|
$
-
|
$
-
|
$
-
|
$
-
|
||||||||||||||||||||||
Shares
issued for cash at $.0326
|
4,299,860
|
4,300
|
135,680
|
|
(97,245)
|
|
|
|
42,735
|
|||||||||||||||||||||||||
Shares
issued for services at $.0139
|
514,674
|
515
|
11,801
|
|
|
(11,177)
|
|
|
1,139
|
|||||||||||||||||||||||||
Amortization
of deferred expense
|
521
|
|
|
521
|
||||||||||||||||||||||||||||||
Comprehensive
loss—foreign currency translation adjustment
|
29,905
|
|
29,905
|
|||||||||||||||||||||||||||||||
Net
loss for the period from inception to April 30, 2002
|
(95,901)
|
(95,901)
|
||||||||||||||||||||||||||||||||
Balance
at April 30, 2002
|
—
|
—
|
4,814,534
|
4,815
|
147,481
|
—
|
(97,245)
|
(10,656)
|
29,905
|
(95,901)
|
(21,601)
|
|||||||||||||||||||||||
Shares
issued for cash at $1.0677
|
14,601
|
15
|
15,575
|
|
|
|
|
|
15,590
|
|||||||||||||||||||||||||
Shares
issued for services at $.0214
|
219,010
|
219
|
4,472
|
|
|
(3,127)
|
|
|
1,564
|
|||||||||||||||||||||||||
Amortization
of deferred expense
|
3,808
|
|
|
3,808
|
||||||||||||||||||||||||||||||
Receipt
of cash for subscription receivable
|
91,517
|
|
|
|
91,517
|
|||||||||||||||||||||||||||||
Comprehensive
loss—foreign currency translation adjustment
|
1,534
|
|
1,534
|
|||||||||||||||||||||||||||||||
Net
loss for the year ended April 30, 2003
|
(111,456)
|
(111,456)
|
||||||||||||||||||||||||||||||||
Balance
at April 30, 2003
|
—
|
—
|
5,048,145
|
5,049
|
167,528
|
—
|
(5,728)
|
(9,975)
|
31,439
|
(207,357)
|
(19,044)
|
|||||||||||||||||||||||
Shares
issued for cash at $1.2479
|
350,164
|
350
|
436,637
|
|
(81,464)
|
|
|
|
355,523
|
|||||||||||||||||||||||||
Shares
issued for services at $1.2587
|
22,233
|
22
|
27,962
|
|
|
(25,216
|
)
|
|
|
2,768
|
||||||||||||||||||||||||
Amortization
of deferred expense
|
7,691
|
|
|
7,691
|
||||||||||||||||||||||||||||||
Exchange
for loan payment and compensation
|
181,371
|
|
2,909
|
|
|
|
184,280
|
|||||||||||||||||||||||||||
Comprehensive
loss—foreign currency translation adjustment
|
(51,651
|
)
|
|
(51,651
|
)
|
|||||||||||||||||||||||||||||
Net
loss for the year ended April 30, 2004
|
(439,453
|
)
|
(439,453
|
)
|
||||||||||||||||||||||||||||||
Balance
at April 30, 2004
|
—
|
—
|
5,420,542
|
5,421
|
813,498
|
—
|
(84,283
|
)
|
(27,500
|
)
|
(20,212
|
)
|
(646,810
|
)
|
40,114
|
|||||||||||||||||||
Shares
issued for cash at $1.3218
|
374,073
|
374
|
494,069
|
|
|
|
|
|
494,443
|
|||||||||||||||||||||||||
Shares
issued for services at $1.2308
|
21,901
|
22
|
26,933
|
|
|
|
|
|
26,955
|
|||||||||||||||||||||||||
3,650
shares to be issued for service at $1.4973
|
5,465
|
|
|
|
|
5,465
|
||||||||||||||||||||||||||||
Amortization
of deferred expense
|
26,939
|
|
|
26,939
|
||||||||||||||||||||||||||||||
Receipt
of cash for subscription receivable
|
84,283
|
|
|
|
84,283
|
|||||||||||||||||||||||||||||
Options
issued for services
|
257,515
|
|
|
|
|
|
257,515
|
|||||||||||||||||||||||||||
Comprehensive
loss—foreign currency translation adjustment
|
(5,719
|
)
|
|
(5,719
|
)
|
|||||||||||||||||||||||||||||
Net
loss for the year ended April 30, 2005
|
(1,129,290
|
)
|
(1,129,290
|
)
|
||||||||||||||||||||||||||||||
Balance
at April 30, 2005
|
—
|
—
|
5,816,516
|
5,817
|
1,592,015
|
5,465
|
—
|
(561
|
)
|
(25,931
|
)
|
(1,776,100
|
)
|
(199,295
|
)
|
|
|
Preferred
|
Stock
|
Common
|
Stock
|
Additional
Paid-in
|
Shares
to
be
|
Subscription
|
Deferred
Equity
Based-
|
Accumulated
other
Comprehensive
Loss-Foreign
Currency
Translation
|
|
Deficit
Accumulated
During
Development
|
|
Total
Stockholders'
Equity
|
||||||||||||||||||||
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Capital
|
|
Issued
|
|
Receivable
|
|
Expense
|
|
Adjustments
|
Stage
|
(Deficit)
|
||||||||||||||
Write
off foreign currency translation adjustment
|
25,931
|
25,931
|
||||||||||||||||||||||||||||||||
Shares
issued for cash at $1.5656
|
12,669
|
13
|
19,821
|
19,834
|
||||||||||||||||||||||||||||||
Shares
issued for prior service
|
3,650
|
3
|
5,462
|
(5,465
|
) |
—
|
||||||||||||||||||||||||||||
Amortization
of deferred expense
|
561
|
561
|
||||||||||||||||||||||||||||||||
Options
issued for services
|
300,616
|
300,616
|
||||||||||||||||||||||||||||||||
Recapitalization
with Bridge Oncology
|
7,865,000
|
7,865
|
(92,335
|
) |
(84,470
|
) | ||||||||||||||||||||||||||||
Beneficial
conversion feature associated with convertible debt
financing
|
364,721
|
364,721
|
||||||||||||||||||||||||||||||||
Convertible
Series A Preferred Stock issued for cash at $10,000 (net
of issuance costs
of $544,169)
|
464.0000
|
0.464
|
4,095,830
|
4,095,830
|
||||||||||||||||||||||||||||||
Convertible
Series A Stock issued on conversion of notes payable
|
128.6318
|
0.1286
|
1,286,318
|
1,286,318
|
||||||||||||||||||||||||||||||
Deemed
dividend on account of beneficial conversion feature associated
with
issuance of Convertible Series A Preferred Stock
|
1,522,317
|
(1,522,317
|
)
|
—
|
||||||||||||||||||||||||||||||
Issuance
costs on warrants issued to placement agent in connection
with the
Convertible Series A Preferred Stock
|
(429,757
|
)
|
(429,757
|
)
|
||||||||||||||||||||||||||||||
Discount
on warrant issued with Convertible Series A Preferred
Stock
|
(2,048,531
|
)
|
(2,048,531
|
)
|
||||||||||||||||||||||||||||||
Recapitalization
with Hibshman Optical Corp.
|
576,700
|
577
|
(7,708
|
)
|
(7,131
|
)
|
||||||||||||||||||||||||||||
Warrant
expense
|
92,689
|
92,689
|
||||||||||||||||||||||||||||||||
Net
loss for the year ended April 30, 2006
|
(5,002,091
|
)
|
(5,002,091
|
)
|
||||||||||||||||||||||||||||||
Balance
at April 30, 2006
|
592.6318
|
$
|
0.5926
|
14,274,534
|
$
|
14,275
|
$
|
6,701,458
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
(8,300,508
|
)
|
$
|
(1,584,775
|
)
|
||||||||||||
Options
issued for services
|
739,000
|
739,000
|
||||||||||||||||||||||||||||||||
Warrant
expense
|
163,920
|
163,920
|
||||||||||||||||||||||||||||||||
Conversion
of preferred stock
|
(1.000
|
)
|
(.0010
|
)
|
18,069
|
18
|
(18
|
)
|
—
|
|||||||||||||||||||||||||
Net
loss for the year ended April 30, 2007
|
(7,495,637
|
)
|
(7,495,637
|
)
|
||||||||||||||||||||||||||||||
Balance
at April 30, 2007
|
591.6318
|
$
|
0.5916
|
14,292,603
|
$
|
14,293
|
$
|
7,604,360
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
(15,796,145
|
)
|
$
|
(8,177,492
|
)
|
Year
ended April
30,
|
From
Inception
of
operations
(April
19, 2001)
to
|
|||||||||
2007
|
2006
|
April
30,
2007
|
||||||||
Cash
flows provided by (used
for) operating activities:
|
||||||||||
Net
loss
|
$
|
(7,495,637
|
)
|
$
|
(5,002,091
|
)
|
$
|
(14,273,828
|
)
|
Adjustments
to reconcile net
loss to net cash provided by (used for) operating
activities:
|
||||||||||
Depreciation
|
5,462
|
1,496
|
6,994
|
Gain
on sale of equipment
|
(622
|
)
|
—
|
(622
|
)
|
Amortization
of stock based expense
|
—
|
561
|
39,520
|
|||||||
Write
off foreign currency translation adjustment
|
—
|
25,931
|
25,931
|
|||||||
Change
in fair value of warrant liabilities
|
2,931,118
|
(137,543
|
)
|
2,793,575
|
|
|||||
Shares
issued for services and compensation
|
—
|
—
|
219,262
|
|||||||
Gain
on settlement of debts
|
—
|
(5,049
|
)
|
(5,049
|
)
|
|||||
Options
expense
|
739,000
|
300,616
|
1,297,131
|
|||||||
Warrant
expense
|
163,920
|
92,689
|
256,609
|
|||||||
Interest
expense related to beneficial conversion feature on
convertible
note
|
—
|
364,721
|
364,721
|
|||||||
Interest
expense related to warrants issued on convertible note
|
—
|
514,981
|
514,981
|
|||||||
Changes
in assets and
liabilities:
|
||||||||||
(Increase)
decrease in
assets—
|
||||||||||
VAT
receivable
|
1,628
|
61,952
|
3,444
|
|||||||
Restricted
funds
|
150,048
|
(152,048
|
)
|
(2,000
|
)
|
|||||
Prepaid
expenses
|
47,767
|
(82,166
|
)
|
(43,037
|
)
|
|||||
Deposits
|
2,627
|
(2,700
|
)
|
(73
|
)
|
|||||
Increase
(decrease) in
liabilities:
|
||||||||||
Accounts
payable
|
516,222
|
199,086
|
776,723
|
|||||||
Accrued
liabilities
|
1,052,994
|
137,846
|
1,354,412
|
|||||||
Liquidated
damages
|
35,200
|
—
|
35,200
|
|||||||
Deferred
revenue
|
(1,429
|
)
|
8,572
|
7,143
|
||||||
Due
to officer and related party
|
233,874
|
(186,263
|
)
|
95,980
|
||||||
Net
cash used for operating activities
|
(1,617,828
|
)
|
(3,859,409
|
)
|
(6,532,983
|
)
|
||||
Cash
flows used for investing
activities:
|
||||||||||
Purchase
of equipment
|
—
|
(21,391
|
)
|
(24,824
|
)
|
|||||
Sale
of equipment
|
2,000
|
—
|
2,000
|
|||||||
Net
cash used for investing activities
|
2,000
|
(21,391
|
)
|
(22,824
|
)
|
|||||
Cash
flows provided by
financing activities:
|
||||||||||
Loan
payable—related party
|
—
|
—
|
79,402
|
|||||||
Loan
payment—related party
|
—
|
—
|
(7,367
|
)
|
||||||
Proceeds
from convertible note-related party
|
—
|
1,250,000
|
1,250,000
|
|||||||
Proceeds
from note payable - related party
|
33,462
|
—
|
33,462
|
|||||||
Proceeds
from issuance of common stock
|
—
|
19,834
|
928,125
|
|||||||
Proceeds
from issuance of preferred stock
|
—
|
4,095,831
|
4,095,831
|
|||||||
Cash
received for subscription receivable
|
—
|
—
|
175,801
|
|||||||
Net
cash provided by financing activities
|
33,462
|
5,365,665
|
6,555,254
|
|||||||
Effect
of exchange rate changes
on cash
|
—
|
—
|
5,938
|
|||||||
Increase
(decrease) in
cash
|
(1,582,366
|
)
|
1,484,865
|
5,385
|
||||||
Cash,
beginning of year
|
1,587,750
|
102,885
|
—
|
|||||||
Cash,
end of year
|
$
|
5,385
|
$
|
1,587,750
|
$
|
5,385
|
||||
Supplemental
disclosure of cash
flow information:
|
||||||||||
Interest
paid
|
54
|
$
|
1,016,020
|
$
|
1,016,074
|
|||||
Income
tax paid
|
$
|
3,717
|
$
|
2,339
|
$
|
6,056
|
||||
Supplemental
disclosure of
non-cash operating and financing activities:
|
||||||||||
Loan
reduction with shares
|
$
|
—
|
$
|
—
|
$
|
2,909
|
||||
Issuance
of warrants in conjunction with convertible preferred
stock
|
$
|
—
|
$
|
2,341,785
|
$
|
2,341,785
|
||||
Deemed
dividends related to convertible preferred stock
|
$
|
—
|
$
|
1,522,317
|
$
|
1,522,317
|
||||
Conversion
of note and accrued interest
|
$
|
—
|
$
|
1,286,318
|
$
|
1,286,318
|
2007
|
2006
|
|
Convertible
preferred stock
|
9,859,125
|
9,877,194
|
Stock
options
|
3,483,163
|
3,825,249
|
Warrants
|
7,102,838
|
6,952,838
|
Total
|
20,445,126
|
20,655,281
|
a.
|
Permits
fair value remeasurement for any hybrid financial
instrument that contains
an embedded derivative that otherwise would
require
bifurcation;
|
|
b.
|
Clarifies
which interest-only strips and principal-only
strips are not subject to
the requirements of Statement
133;
|
c.
|
Establishes
a requirement to evaluate interests in
securitized financial assets to
identify interests that are freestanding
derivatives or that are hybrid
financial instruments that contain an embedded
derivative requiring
bifurcation;
|
|
d.
|
Clarifies
that concentrations of credit risk in the
form of subordination are not
embedded derivatives; and
|
|
e.
|
Amends
Statement 140 to eliminate the prohibition
on a qualifying special-purpose
entity from holding a derivative financial
instrument that pertains to a
beneficial interest other than another
derivative financial
instrument.
|
Payroll
& vacation
|
$
|
472,014
|
||
Accounting
& legal
|
326,325
|
|||
Consultant
|
13,200
|
|||
$
|
811,539
|
April
30,
2007
|
April
30,
2006
|
||||||
Current
Taxes:
|
|||||||
Federal
|
$
|
—
|
$
|
—
|
State
|
3,717
|
2,339
|
|||||
Foreign
|
—
|
—
|
|||||
Total
|
$
|
3,717
|
$
|
2,339
|
|||
Deferred
Taxes:
|
|||||||
Federal
|
—
|
—
|
|||||
State
|
—
|
—
|
|||||
Foreign
|
—
|
—
|
|||||
Total
|
—
|
—
|
April
30,
2007
|
April
30,
2006
|
||||||
US
Net Operating Loss Carryforwards
at statutory rate
|
$
|
2,602,000
|
$
|
1,107,000
|
UK
Net Operating Loss Carryforwards
at statutory rate
|
703,000
|
703,000
|
Total
|
3,305,000
|
1,810,000
|
Less
Valuation Allowance
|
(3,305,000
|
)
|
(1,810,000
|
)
|
Net
Deferred Tax assets
|
$
|
—
|
$
|
—
|
April
30,
2007
|
April
30,
2006
|
||||||
Income
tax (benefit) expense at statutory
rate
|
$
|
(2,549,000
|
)
|
(1,701,000
|
)
|
Non
Deductible Expenses at statutory rate
|
1,050,000
|
335,000
|
Other
|
4,000
|
18,000
|
Change
in valuation allowance at statutory
rate
|
1,495,000
|
1,348,000
|
|||||
$ | - | $ |
Year
ended
April
30,
|
||
2007
|
2006
|
|
Expected
volatility
|
80.17
to 81.38%
|
101.80%
|
Weighted-average
volatility
|
80.41%
|
101.80%
|
Expected
dividend yield
|
0%
|
0%
|
Expected
term in years
|
6.0
|
6.0
to 7.0
|
Risk-free
interest rate
|
4.8%
to 5.1%
|
4.1%
to 4.6%
|
Shares
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Term
(Years)
|
Aggregate
Intrinsic
Value
|
||||||||||
Outstanding
at April 30, 2005
|
2,204,701
|
$
|
1.23
|
7.6
|
$
|
44,094
|
|||||||
Granted
|
1,781,170
|
0.60
|
|||||||||||
Exercised
|
—
|
||||||||||||
Forfeited
|
(160,622
|
)
|
1.23
|
||||||||||
Expired
|
—
|
||||||||||||
Outstanding
at April 30, 2006
|
3,825,249
|
0.94
|
7.9
|
$
|
65,696
|
||||||||
Granted
|
122,500
|
0.60
|
|||||||||||
Exercised
|
—
|
||||||||||||
Forfeited
|
(339,417
|
)
|
0.60
|
||||||||||
Expired
|
(125,169
|
)
|
1.15
|
||||||||||
Outstanding
at April 30, 2007
|
3,483,163
|
$
|
0.95
|
0.1
|
$
|
1,040,399
|
|||||||
Exercisable
at April 30, 2007
|
3,483,163
|
$
|
0.95
|
0.1
|
$
|
1,040,399
|
Shares
|
Weighted
Average
Grant
Date Fair
Value
|
Non-vested
at April 30, 2006
|
1,849,128
|
$
|
0.43
|
Granted
|
122,500
|
$
|
0.43
|
||||
Vested
|
(1,632,211
|
)
|
$
|
0.48
|
|||
Forfeited
|
(339,417
|
)
|
$
|
0.18
|
|||
Non-vested
at April 30, 2007
|
-0-
|
Shares
|
Wtd.
Avg.
Exercise
Price
|
||||||
Outstanding April 30, 2005 |
—
|
||||||
Granted
|
6,952,838
|
$
|
.62
|
||||
Exercised
|
—
|
Forfeited |
—
|
||||||
Expired
|
—
|
||||||
Outstanding
April 30, 2006
|
6,952,838
|
$
|
.62
|
||||
Granted
|
150,000
|
$
|
.01
|
||||
Exercised
|
—
|
||||||
Forfeited
|
—
|
||||||
Expired
|
—
|
||||||
Outstanding
April 30, 2007
|
7,102,838
|
$
|
.61
|
Warrants
Outstanding
|
Warrants
Exercisable
|
Exercise
Prices
|
Number
Outstanding
|
Wtd.
Avg
Remaining
Contr.
Life
|
Wtd.
Avg
Exercise
Price
|
Number
Exercisable
|
Wtd.
Avg
Exercise
Price
|
|||||||||||
$0.01
|
1,166,534
|
5.8
years
|
$
|
0.01
|
1,166,534
|
$
|
0.01
|
|||||||||
$0.60
|
987,720
|
4.8
years
|
$
|
0.60
|
987,720
|
$
|
0.60
|
|||||||||
$0.75
|
4,938,597
|
4.8
years
|
$
|
0.75
|
4,938,597
|
$
|
0.75
|
|||||||||
$2.25
|
9,987
|
3.1
years
|
$
|
2.25
|
9,987
|
$
|
2.25
|
(Unaudited)
October
31, 2007
|
(Audited)
April
30,
2007
|
||||||
Assets
|
|||||||
Current
assets:
|
|||||||
Cash
|
$
|
1,424
|
$
|
5,385
|
|||
Prepaid
expenses
|
25,391
|
43,308
|
|||||
Total
current assets
|
26,815
|
48,693
|
|||||
Office
equipment, net of
accumulated depreciation of
$9,441 and $6,750 for the period
ended October
31, 2007 and April 30, 2007,
respectively
|
13,870
|
16,560
|
|||||
Other
assets:
|
|||||||
Restricted
funds
|
—
|
2,000
|
|||||
Deposits
|
73
|
73
|
|||||
Total
other assets
|
73
|
2,073
|
|||||
Total
assets
|
$
|
40,758
|
$
|
67,326
|
|||
Liabilities
and Stockholders’ Deficit
|
|||||||
Current
liabilities:
|
|||||||
Accounts
payable
|
$
|
1,027,819
|
$
|
774,022
|
|||
Due
to related parties
|
281,335
|
241,874
|
|||||
Accrued
expenses
|
969,121
|
811,539
|
|||||
Accrued
research and development expenses
|
354,733
|
554,733
|
|||||
Note
payable
|
822,712
|
33,462
|
|||||
Liquidated
damages related to Series A
preferred stock and warrants
|
35,200
|
35,200
|
|||||
Deferred
revenue
|
6,429
|
7,143
|
|||||
Warrant
liabilities
|
117,636
|
5,786,844
|
|||||
Total
current liabilities
|
3,614,985
|
8,244,817
|
|||||
Stockholders’
deficit:
|
|||||||
Preferred
stock - $0.001 par value, 20,000,000
shares authorized Series A
Convertible Preferred Stock,
$0.001 par value, 2,000 shares
designated,
591.6318 issued and outstanding
as of October 31, 2007 and
April 30,
2007
|
1
|
1
|
|||||
Common
stock, $0.001 par value, 100,000,000
shares authorized, 15,459,137
shares
issued and outstanding as of
October 31, 2007 and April
30,
2007
|
15,460
|
14,293
|
|||||
Additional
paid-in capital
|
7,614,859
|
7,604,360
|
|||||
Deficit
accumulated during development
stage
|
(11,204,549
|
)
|
(15,796,145
|
)
|
|||
Total
stockholders’ deficit
|
(3,574,229
|
)
|
(8,177,491
|
)
|
|||
Total
liabilities and stockholders’ deficit
|
$
|
40,756
|
$
|
67,326
|
|||
From Inception
of
Operations
(April 19, 2001) to
October 31,
2007
|
||||||||||||||||
Three
Months Ended
October 31,
|
Six
Months Ended
October 31,
|
|||||||||||||||
2007
|
2006
|
2007
|
2006
|
|||||||||||||
Revenue
|
$
|
357
|
$
|
357
|
$
|
714
|
$
|
714
|
$
|
3,571
|
||||||
Operating
expenses:
|
||||||||||||||||
General
and administrative
|
(293,809
|
)
|
(874,810
|
)
|
(726,685
|
)
|
(1,700,359
|
)
|
(8,063,803
|
)
|
||||||
Research
and development
|
(269,688
|
)
|
(583,318
|
)
|
(321,827
|
)
|
(901,352
|
)
|
(3,422,474
|
)
|
||||||
Loss
from operations
|
(563,140
|
)
|
(1,457,771
|
)
|
(1,047,798
|
)
|
(2,600,997
|
)
|
(11,482,706
|
)
|
||||||
Other
income (expense):
|
||||||||||||||||
Interest
income
|
—
|
11,475
|
5
|
28,554
|
40,437
|
|||||||||||
Interest
expense
|
(20,181
|
)
|
—
|
(27,316
|
)
|
—
|
(1,043,390
|
)
|
||||||||
Liquidated
damages
|
—
|
85,302
|
—
|
(35,200
|
)
|
(35,200
|
)
|
|||||||||
Change
in fair value of warrant liabilities
|
88,157
|
119,762
|
5,669,206
|
394,324
|
2,875,631
|
|||||||||||
Gain
on settlement of debt
|
—
|
—
|
—
|
—
|
5,049
|
|||||||||||
Currency
translation loss
|
(589
|
)
|
(768
|
)
|
(710
|
)
|
(2,002
|
)
|
(34,206
|
)
|
||||||
Income
(loss) before income taxes
|
(495,753
|
)
|
(1,242,000
|
)
|
4,593,387
|
(2,215,321
|
)
|
(9,674,385
|
)
|
|||||||
Income
taxes
|
(1,600
|
)
|
—
|
(1,791
|
)
|
(250
|
)
|
(7,847
|
)
|
|||||||
Net
income (loss)
|
(497,353
|
)
|
(1,242,000
|
)
|
4,591,596
|
(2,215,571
|
)
|
(9,682,232
|
)
|
Deemed
dividends on convertible preferred
stock
|
—
|
—
|
—
|
—
|
(1,522,317
|
)
|
||||||||||
Net
income (loss) applicable to
common shareholders
|
$
|
(497,353
|
)
|
$
|
(1,242,000
|
)
|
$
|
4,591,596
|
$
|
(2,215,571
|
)
|
$
|
(11,204,549
|
)
|
||
Net
income (loss) per share-basic
|
$
|
(0.03
|
)
|
$
|
(0.09
|
)
|
$
|
0.31
|
$
|
(0.16
|
)
|
$
|
(0.84
|
)
|
||
Weighted
average number of shares outstanding—basic
|
14,630,402
|
14,274,534
|
14,630,402
|
14,274,534
|
13,364,892
|
|||||||||||
Net
income (loss) per share-diluted
|
$
|
(0.03
|
)
|
$
|
(0.09
|
)
|
$
|
0.19
|
$
|
(0.16
|
)
|
$
|
(0.84
|
)
|
||
Weighted
average number of shares outstanding—diluted
|
14,630,402
|
14,274,534
|
23,889,527
|
14,274,534
|
13,364,892
|
Additional
Paid-in
Capital
|
Shares
to
be
Issued
|
||||||||||||||||||
Preferred
Stock
|
Common
Stock
|
||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
||||||||||||||||
Balance
at April 19, 2001 (Inception)
|
—
|
$
|
—
|
—
|
$
|
—
|
$
|
—
|
$
|
—
|
|||||||||
Shares
issued for cash at $.0326
|
4,299,860
|
4,300
|
135,680
|
—
|
|||||||||||||||
Shares
issued for services at $.0139
|
514,674
|
515
|
11,801
|
||||||||||||||||
Amortization
of deferred expense
|
|||||||||||||||||||
Comprehensive
loss—foreign currency translation
adjustment
|
|||||||||||||||||||
Net
loss for the period from inception
to April 30, 2002
|
|||||||||||||||||||
Balance
at April 30, 2002
|
—
|
—
|
4,814,534
|
4,815
|
147,481
|
—
|
|||||||||||||
Shares
issued for cash at $1.0677
|
14,601
|
15
|
15,575
|
||||||||||||||||
Shares
issued for services at $.0214
|
219,010
|
219
|
4,472
|
||||||||||||||||
Amortization
of deferred expense
|
|||||||||||||||||||
Receipt
of cash for subscription receivable
|
|||||||||||||||||||
Comprehensive
loss—foreign currency translation
adjustment
|
|||||||||||||||||||
Net
loss for the year ended April
30, 2003
|
|||||||||||||||||||
Balance
at April 30, 2003
|
—
|
—
|
5,048,145
|
5,049
|
167,528
|
—
|
|||||||||||||
Shares
issued for cash at $1.2479
|
350,164
|
350
|
436,637
|
||||||||||||||||
Shares
issued for services at $1.2587
|
22,233
|
22
|
27,962
|
||||||||||||||||
Amortization
of deferred expense
|
|||||||||||||||||||
Exchange
for loan payment and compensation
|
181,371
|
||||||||||||||||||
Comprehensive
loss—foreign currency translation
adjustment
|
|||||||||||||||||||
Net
loss for the year ended April
30, 2004
|
|||||||||||||||||||
Balance
at April 30, 2004
|
—
|
—
|
5,420,542
|
5,421
|
813,498
|
—
|
|||||||||||||
Shares
issued for cash at $1.3218
|
374,073
|
374
|
494,069
|
||||||||||||||||
Shares
issued for services at $1.2308
|
21,901
|
22
|
26,933
|
||||||||||||||||
3,650
shares to be issued for service
at $1.4973
|
5,465
|
||||||||||||||||||
Amortization
of deferred expense
|
|||||||||||||||||||
Receipt
of cash for subscription receivable
|
|||||||||||||||||||
Options
issued for services
|
257,515
|
||||||||||||||||||
Comprehensive
loss—foreign currency translation
adjustment
|
|||||||||||||||||||
Net
loss for the year ended April
30, 2005
|
|||||||||||||||||||
Balance
at April 30, 2005
|
—
|
—
|
5,816,516
|
5,817
|
1,592,015
|
5,465
|
|||||||||||||
Write
off foreign currency translation
adjustment
|
|||||||||||||||||||
Shares
issued for cash at $1.5656
|
12,669
|
13
|
19,821
|
||||||||||||||||
Shares
issued for prior service
|
3,650
|
3
|
5,462
|
(5,465
|
)
|
||||||||||||||
Amortization
of deferred expense
|
|||||||||||||||||||
Options
issued for services
|
300,616
|
||||||||||||||||||
Recapitalization
with Bridge Oncology
|
7,865,000
|
7,865
|
(92,335
|
)
|
Beneficial
conversion feature associated
with convertible debt
financing
|
364,721
|
||||||||||||||||||
Convertible
Series A Preferred shares issued
for cash at $10,000
(net
of issuance costs of $544,169)
|
464
|
0.464
|
4,095,830
|
||||||||||||||||
Convertible
Series A Shares issued on conversion
of notes payable
|
128.6318
|
0.1286
|
1,286,318
|
||||||||||||||||
Deemed
dividend on account of beneficial
conversion feature associated
with
issuance of Convertible Series
A Preferred Shares
|
1,522,317
|
||||||||||||||||||
Issuance
costs on warrants issued to
placement agent in connection
with the
Convertible Series A Preferred
stock
|
(429,757
|
)
|
|||||||||||||||||
Discount
on warrant issued with Convertible
Series A Preferred
stock
|
(2,048,531
|
)
|
|||||||||||||||||
Recapitalization
with Hibshman Optical Corp.
|
576,700
|
577
|
(7,708
|
)
|
|||||||||||||||
Warrant
expense
|
92,689
|
||||||||||||||||||
Net
loss for the year ended April
30, 2006
|
|||||||||||||||||||
Balance
at April 30, 2006
|
592.6318
|
.5926
|
14,274,535
|
14,275
|
6,701,458
|
—
|
|||||||||||||
Options
issued for services
|
739,000
|
||||||||||||||||||
Warrant
expense
|
163,920
|
||||||||||||||||||
Conversion
of preferred stock
|
(1.000
|
)
|
(.0010
|
)
|
18,069
|
18
|
(18
|
)
|
|||||||||||
Net
loss for the year ended April
30, 2007
|
|||||||||||||||||||
Balance
at April 30, 2007
|
591.6318
|
.5916
|
14,292,604
|
14,293
|
7,604,360
|
||||||||||||||
From
Inception of
Operations
(April
19, 2001) to
October
31, 2007
|
||||||||||
Six
Months Ended October 31,
|
||||||||||
2007
|
2006
|
|||||||||
Cash
flows provided by (used for)
operating activities:
|
||||||||||
Net
income (loss)
|
$
|
4,591,596
|
$
|
(2,215,571
|
)
|
$
|
(9,682,232
|
)
|
||
Adjustments
to reconcile net loss to net
cash provided by (used for)
operating
activities:
|
||||||||||
Depreciation
|
2,690
|
2,770
|
9,684
|
|||||||
Gain
on sale of equipment
|
—
|
(622
|
)
|
(622
|
)
|
|||||
Amortization
of stock based expense
|
—
|
—
|
39,520
|
|||||||
Write
off foreign currency translation
adjustment
|
—
|
—
|
25,931
|
|||||||
Change
in fair value of warrant liabilities
|
(5,669,206
|
)
|
(394,324
|
)
|
(2,875,631
|
)
|
||||
Shares
issued for services and compensation
|
—
|
—
|
219,262
|
|||||||
Gain
on settlement of debts
|
—
|
—
|
(5,049
|
)
|
||||||
Options
expense
|
—
|
124,376
|
1,297,131
|
|||||||
Warrants
expense
|
—
|
—
|
256,609
|
|||||||
Interest
expense related to beneficial
conversion feature on convertible
note
|
—
|
—
|
364,721
|
|||||||
Interest
expense related to warrants
issued on convertible note
|
—
|
—
|
514,981
|
|||||||
Changes
in assets and liabilities:
|
||||||||||
(Increase)
decrease in assets -
|
||||||||||
VAT
receivable
|
—
|
1,628
|
3,444
|
|||||||
Other
receivable
|
—
|
(22,509
|
)
|
—
|
||||||
Restricted
funds
|
2,000
|
(2,269
|
)
|
—
|
||||||
Prepaid
expenses
|
17,917
|
33,093
|
(25,120
|
)
|
||||||
Deposits
|
—
|
—
|
(73
|
)
|
||||||
Increase
(decrease) in liabilities:
|
||||||||||
Accounts
payable
|
229,784
|
214,931
|
1,012,445
|
|||||||
Accrued
liabilities
|
(42,418
|
)
|
783,221
|
1,311,994
|
||||||
Liquidated
damages
|
—
|
35,200
|
35,200
|
|||||||
Deferred
revenue
|
(714
|
)
|
(714
|
)
|
6,429
|
|||||
Due
to officers and related parties
|
75,140
|
152,003
|
171,120
|
|||||||
Net
cash used for operating activities
|
(793,211
|
)
|
(1,288,787
|
)
|
(7,320,256
|
)
|
||||
Cash
flows used for investing activities:
|
||||||||||
Purchase
of equipment
|
—
|
—
|
(24,824
|
)
|
||||||
Proceeds
from sale of equipment
|
—
|
2,000
|
2,000
|
|||||||
Net
cash used for investing activities
|
—
|
2,000
|
(22,824
|
)
|
||||||
Cash
flows provided by financing
activities:
|
||||||||||
Loan
payable—related party
|
—
|
—
|
79,402
|
|||||||
Loan
payment-related party
|
—
|
—
|
(7,367
|
)
|
||||||
Proceeds
from convertible note-related
party
|
—
|
—
|
1,250,000
|
|||||||
Proceeds
from note payable
|
789,250
|
—
|
822,712
|
|||||||
Proceeds
from issuance of common stock
|
—
|
—
|
928,125
|
|||||||
Proceeds
from issuance of preferred
stock
|
—
|
—
|
4,095,831
|
|||||||
Cash
received for subscription receivable
|
—
|
—
|
175,801
|
|||||||
Net
cash provided by financing
activities
|
789,250
|
—
|
7,344,504
|
|||||||
Effect
of exchange rate changes on
cash
|
—
|
—
|
—
|
|||||||
Increase
(decrease) in cash
|
(3,961
|
)
|
(1,286,787
|
)
|
1,424
|
|||||
Cash,
beginning of
period
|
5,385
|
1,587,751
|
—
|
|||||||
Cash,
end of
period
|
$
|
1,424
|
$
|
300,964
|
$
|
1,424
|
||||
Supplemental
disclosure of cash flow information:
|
||||||||||
Interest
paid
|
$
|
—
|
$
|
—
|
$
|
—
|
||||
Income
tax paid
|
$
|
—
|
$
|
—
|
$
|
—
|
||||
Supplemental
disclosure of non-cash operating
and financing activities:
|
||||||||||
Loan
reduction with shares
|
$
|
—
|
$
|
—
|
$
|
2,909
|
||||
Receivable
from issuance of convertible
stock
|
$
|
—
|
$
|
—
|
$
|
—
|
||||
Issuance
of warrants in conjunction
with convertible preferred
stock
|
$
|
—
|
$
|
—
|
$
|
2,341,785
|
||||
Deemed
dividends related to convertible
preferred stock
|
$
|
—
|
$
|
—
|
$
|
1,522,317
|
||||
Conversion
of note and accrued interest
|
$
|
—
|
$
|
—
|
$
|
1,286,318
|
||||
Accrued
issuance costs related to convertible
stock
|
$
|
—
|
$
|
—
|
$
|
—
|
||||
1.
|
ORGANIZATION,
BASIS OF PRESENTATION, AND
NATURE OF
OPERATIONS
|
2007
|
||||||||||
Three
Months
Ended
October 31
|
Six
Months
Ended
October 31
|
2006
|
||||||||
Convertible
preferred stock
|
9,859,125
|
9,859,125
|
9,877,194
|
|||||||
Stock
options
|
—
|
—
|
3,642,747
|
|||||||
Warrants
|
5,936,304
|
7,102,838
|
6,952,838
|
|||||||
Total
|
15,795,429
|
16,961,963
|
20,472,779
|
|||||||
a.
|
Permits
fair value remeasurement for
any hybrid financial instrument
that contains
an embedded derivative that
otherwise would require
bifurcation;
|
|
b.
|
Clarifies
which interest-only strips
and principal-only strips are
not subject to
the requirements of Statement
133;
|
|
c.
|
Establishes
a requirement to evaluate interests
in securitized financial assets
to
identify interests that are
freestanding derivatives or
that are hybrid
financial instruments that
contain an embedded derivative
requiring
bifurcation;
|
|
d.
|
Clarifies
that concentrations of credit
risk in the form of subordination
are not
embedded derivatives; and
|
|
e.
|
Amends
Statement 140 to eliminate
the prohibition on a qualifying
special-purpose
entity from holding a derivative
financial instrument that pertains
to a
beneficial interest other than
another derivative financial
instrument.
|
2.
|
PRIVATE
PLACEMENT
|
3.
|
LIQUIDATED
DAMAGES AND WARRANT LIABILITIES
|
Number
of
shares
|
Weighted
Average
Exercise
Price
|
||||||
Balance—April
30, 2007
|
7,102,838
|
0.61
|
|||||
Granted
|
—
|
—
|
|||||
Exercised
|
1,166,534
|
0.001
|
|||||
Forfeited
|
—
|
—
|
|||||
Expired
|
—
|
—
|
|||||
Balance—October
31, 2007
|
5,936,304
|
0.61
|
|||||
Warrants
Outstanding
|
Warrants
Exercisable
|
|||||||||||||||||
Exercise
Prices
|
Number
Outstanding
|
Wtd.
Avg
Remaining
Contr.
Life
|
Wtd.
Avg
Exercise
Price
|
Number
Exercisable
|
Wtd.
Avg
Exercise
Price
|
|||||||||||||
$
|
0.60
|
987,720
|
4.2
years
|
$
|
0.60
|
987,720
|
$
|
0.60
|
||||||||||
$
|
0.75
|
4,938,597
|
4.2
years
|
$
|
0.75
|
4,938,597
|
$
|
0.75
|
||||||||||
$
|
2.25
|
9,987
|
2.5
years
|
$
|
2.25
|
9,987
|
$
|
2.25
|
4.
|
EMPLOYMENT
AND CONSULTING AGREEMENTS
|
5.
|
STOCK-
BASED COMPENSATION
|
6.
|
RELATED
PARTY TRANSACTIONS
|
7.
|
SECURED
NOTE
|
8.
|
MERGER
AGREEMENT
|
9.
|
SUBSEQUENT
EVENTS
|
Access
|
Somanta
|
Pro
Forma
Adjustments
|
Pro
Forma
Combined
|
|||||||||||||
ASSETS
|
||||||||||||||||
Current
assets
|
||||||||||||||||
Cash
and cash equivalents
|
$
|
661,000
|
$
|
2,000
|
$
|
663,000
|
||||||||||
Short
term investments, at cost
|
515,000
|
-
|
515,000
|
|||||||||||||
Receivables
|
861,000
|
-
|
(823,000 | ) |
(d
|
) |
38,000
|
|||||||||
Prepaid
expenses and other current
expenses
|
530,000
|
25,000
|
(410,000
|
) |
(c
|
) |
145,000
|
|||||||||
Total
current assets
|
2,567,000
|
27,000
|
1,361,000
|
|||||||||||||
Property
and equipment, net
|
156,000
|
14,000
|
170,000
|
|||||||||||||
Patents
net
|
752,000
|
-
|
752,000
|
|||||||||||||
Other
assets
|
25,000
|
-
|
25,000
|
|||||||||||||
Total
assets
|
$
|
3,500,000
|
$
|
41,000
|
$
|
2,308,000
|
||||||||||
LIABILITIES
AND STOCKHOLDERS’ DEFICIT
|
||||||||||||||||
Current
liabilities
|
||||||||||||||||
Accounts
payables and accrued expenses
|
$
|
1,595,000
|
$
|
2,353,000
|
(410,000
|
) |
(c,d
|
)
|
$
|
3,538,000
|
||||||
Due
to related parties
|
-
|
281,000
|
281,000
|
|||||||||||||
Liquidated
damages related to Series A
|
-
|
35,000
|
(35,000
|
)
|
(b
|
)
|
-
|
|||||||||
Accrued
interest payable
|
1,023,000
|
-
|
1,023,000
|
|||||||||||||
Deferred
revenues
|
1,167,000
|
6,000
|
1,173,000
|
|||||||||||||
Warrant liabilities | - | 118,000 |
(118,000
|
)
|
(b
|
)
|
- | |||||||||
Current
portion of long-term debt
net
of discount
|
11,406,000
|
823,000
|
(823,000
|
)
|
(d
|
)
|
11,406,000
|
|||||||||
Total
current liabilities
|
15,191,000
|
3,616,000
|
17,421,000
|
|||||||||||||
Long-term
debt
|
5,500,000
|
-
|
5,500,000
|
|||||||||||||
Total
liabilities
|
20,691,000
|
3,616,000
|
22,921,000
|
|||||||||||||
Stockholders’
deficit
|
||||||||||||||||
Preferred
stock
|
-
|
-
|
-
|
|||||||||||||
Common
stock
|
36,000
|
15,000
|
15,000
(15,000
|
)
|
(a
(b
|
)
)
|
51,000
|
|||||||||
Additional
paid-in capital
|
69,687,000
|
7,615,000
|
7,485,000
(7,615,000
|
)
|
(a
(b
|
)
)
|
77,172,000
|
|||||||||
Notes
receivable from stockholders
|
(1,045,000
|
)
|
-
|
(1,045,000
|
)
|
|||||||||||
Treasury
stock, at cost
|
(4,000
|
)
|
-
|
(4,000
|
)
|
|||||||||||
Accumulated
deficit
|
(85,865,000
|
)
|
(11,205,000
|
)
|
(7,500,000
|
)
|
(a
|
)
|
(96,787,000
|
)
|
||||||
(3,422,000
11,205,000
|
)
|
(b
(b
|
)
)
|
|||||||||||||
Total
stockholders’ deficit
|
(17,191,000
|
)
|
(3,575,000
|
)
|
(20,613,000
|
)
|
||||||||||
Total
liabilities and stockholders’ deficit
|
$
|
3,500,000
|
$
|
41,000
|
$
|
2,308,000
|
|
Note
1: The above statement gives effect to the following pro forma adjustments
necessary to reflect the merger of Access and Somanta, as if the
transaction had occurred September 30, 2007. Somanta statements used
were October 31, 2007.
|
|
a)
|
To
record the exchange, for accounting purposes, by Somanta shareholders
of
their common stock (valued at $7,500,000) for 1,500,000 shares of
Access
(or 1,500,000 shares valued at the estimated stock price of $5.00
per
share) and record $1,000,000 in new warrant liability. The value
placed on
the shares was determined based on negotiation between the companies
of
the amount of Access shares to issue to Somanta shareholders and
the
estimated stock price of $5.00 per share. The excess purchase price
over
the fair value of Somanta's assets acquired is being charged to
deficit.
|
|
b)
|
To
eliminate the shareholders equity section and warrant liabilities
of
Somanta in connection with the merger and credit the net equity to
combined deficit.
|
|
c)
|
Accrual
of $410,000 of estimated legal, accounting and other professional
fees
relating to the merger.
|
|
d)
|
Eliminate
intercompany notes receivable and payable of
$823,000.
|
Access
|
Somanta
|
Pro
Forma
Combined
|
||||||||
Revenue
|
$
|
6,000
|
$
|
1,000
|
$
|
7,000
|
||||
Expenses
|
||||||||||
Research
and development
|
1,532,000
|
568,000
|
2,100,000
|
|||||||
General
and administrative
|
3,252,000
|
1,969,000
|
5,221,000
|
|||||||
Depreciation
and amortization
|
210,000
|
-
|
210,000
|
|||||||
Total
expenses
|
4,994,000
|
2,537,000
|
7,531,000
|
|||||||
Loss
from operations
|
(4,988,000
|
)
|
(2,536,000
|
)
|
(7,524,000
|
)
|
||||
Interest
and miscellaneous income
|
72,000
|
12,000
|
84,000
|
|||||||
Interest
and other expenses
|
(3,277,000
|
)
|
(27,000
|
) |
(3,304,000
|
)
|
||||
Change
in fair value of warrant liabilities
|
-
|
5,807,000
|
|
5,807,000
|
|
|||||
Currency
translation loss
|
-
|
(2,000
|
)
|
(2,000
|
)
|
|||||
(3,205,000
|
)
|
5,790,000
|
|
2,585,000
|
|
|||||
Loss
From Operations
|
(8,193,000
|
)
|
3,254,000
|
|
(4,939,000
|
)
|
||||
Income
Tax
|
-
|
-
|
(4,000
|
) | ||||||
Net
loss
|
$
|
(8,193,000
|
)
|
$
|
3,254,000
|
|
$
|
(4,943,000
|
)
|
|
Basic
and diluted loss per
common
share
|
$
|
(2.31
|
)
|
$
|
0.22
|
|
$
|
(0.98
|
)
|
|
Weighted
average basic and
diluted
common shares outstanding
|
3,544,181
|
14,630,402
|
5,044,181
|
Historical
|
3,544,181
|
|
Somanta
equivalent shares giving effect to the merger
|
1,500,000
|
|
Total
|
5,044,181
|
Access
|
Somanta
|
Pro
Forma
Combined
|
||||||||
Revenue
|
$
|
-
|
$
|
1,000
|
$
|
1,000
|
||||
Expenses
|
||||||||||
Research
and development
|
2,053,000
|
1,239,000
|
3,292,000
|
|||||||
General
and administrative
|
2,813,000
|
3,313,000
|
6,126,000
|
|||||||
Depreciation
and amortization
|
309,000
|
-
|
309,000
|
|||||||
Total
expenses
|
5,175,000
|
4,552,000
|
9,727,000
|
|||||||
Loss
from operations
|
(5,175,000
|
)
|
(4,551,000
|
)
|
(9,726,000
|
)
|
||||
Interest
and miscellaneous income
|
294,000
|
28,000
|
322,000
|
|||||||
Interest
and other expenses
|
(7,436,000
|
)
|
-
|
(7,436,000
|
)
|
|||||
Liquidated
damages
|
-
|
(35,000
|
)
|
(35,000
|
)
|
|||||
Change
in fair value of warrant liabilities
|
(1,107,000
|
)
|
(2,931,000
|
)
|
(4,038,000
|
)
|
||||
Currency
translation loss
|
-
|
(3,000
|
)
|
(3,000
|
)
|
|||||
(8,249,000
|
)
|
(2,941,000
|
)
|
(11,190,000
|
)
|
|||||
Net
loss before discontinued
operations
and before tax benefit
|
(13,424,000
|
)
|
(7,492,000
|
)
|
(20,916,000
|
)
|
||||
Income
tax benefit
|
173,000
|
(4,000
|
)
|
169,000
|
||||||
Loss
from continuing operations
|
(13,251,000
|
)
|
(7,496,000
|
)
|
(20,747,000
|
)
|
||||
Discontinued
operations, net of
taxes
of $173,000
|
377,000
|
-
|
377,000
|
|||||||
Net
loss
|
$
|
(12,874,000
|
)
|
$
|
(7,496,000
|
)
|
$
|
(20,370,000
|
)
|
|
Basic
and diluted loss per common share
|
||||||||||
Loss
from continuing operations
allocable
to common stockholders
|
$
|
(3.75
|
)
|
$
|
(0.52
|
)
|
$
|
(4.12
|
)
|
|
Discontinued
operations
|
0.10
|
-
|
0.07
|
|||||||
Net
loss allocable to common stockholders
|
$
|
(3.65
|
)
|
$
|
(0.52
|
)
|
$
|
(4.05
|
)
|
|
Weighted
average basic and
diluted
common shares outstanding
|
3,531,934
|
14,274,534
|
5,031,934
|
Historical
|
3,531,934
|
|
Somanta
equivalent shares giving effect to the merger
|
1,500,000
|
|
Total
|
5,031,934
|
SEC
Registration Fee
|
$
|
1,324
|
|
Printing
and Engraving Expenses
|
$
|
2,500
|
|
Legal
Fees and Expenses
|
$
|
20,000
|
|
Accountants'
Fees and Expenses
|
$
|
25,000
|
|
Miscellaneous
Costs
|
$
|
2,176
|
|
Total
|
$
|
51,000
|
Number
|
Description
of
Document
|
2.1
|
Amended
and Restated Agreement of Merger and Plan of Reorganization between
Access
Pharmaceuticals, Inc. and Chemex Pharmaceuticals, Inc., dated as
of
October 31, 1995 (Incorporated by reference to Exhibit A of the our
Registration Statement on Form S-4 dated December 21, 1995, Commission
File No. 33-64031)
|
2.2
|
Agreement
and Plan of Merger, by and among Access Pharmaceuticals, Inc., Somanta
Acquisition Corporation, Somanta Pharmaceuticals, Inc. Somanta
Incorporated and Somanta Limited, dated April 18, 2007. (Incorporated
by
reference to Exhibit 2.1 to our Form 8-K dated April 18,
2007)
|
3.0
|
Articles
of incorporation and bylaws
|
3.1
|
Certificate
of Incorporation (Incorporated by Reference to Exhibit 3(a) of our
Form
8-B dated July 12, 1989, Commission File Number
9-9134)
|
3.3
|
Certificate
of Merger filed January 25, 1996. (Incorporated by reference to Exhibit
E
of our Registration Statement on Form S-4 dated December 21, 1995,
Commission File No. 33-64031)
|
3.4
|
Certificate
of Amendment of Certificate of Incorporation filed January 25, 1996.
(Incorporated by reference to Exhibit E of our Registration Statement
on
Form S-4 dated December 21, 1995, Commission File No.
33-64031)
|
3.5
|
Certificate
of Amendment of Certificate of Incorporation filed July 18, 1996.
(Incorporated by reference to Exhibit 3.8 of our Form 10-K for the
year
ended December 31, 1996)
|
3.6
|
Certificate
of Amendment of Certificate of Incorporation filed June 18, 1998.
(Incorporated by reference to Exhibit 3.8 of our Form 10-Q for the
quarter
ended June 30, 1998
|
3.7
|
Certificate
of Amendment of Certificate of Incorporation filed July 31, 2000.
(Incorporated by reference to Exhibit 3.8 of our Form 10-Q for the
quarter
ended March 31, 2001)
|
3.8
|
Certificate
of Designations of Series A Junior Participating Preferred Stock
filed
November 7, 2001 (Incorporated by reference to Exhibit 4.1.h of our
Registration Statement on Form S-8, dated December 14, 2001, Commission
File No. 333-75136)
|
3.9
|
Amended
and Restated Bylaws (Incorporated by reference to Exhibit 3.1 of
our Form
10-Q for the quarter ended June 30,
1996)
|
3.10
|
Certificate
of Designation of Series A Cumulative Convertible Preferred Stock
filed
November 9, 2007
|
5.1**
|
Opinion
of Bingham McCutchen LLP regarding the legality of the
securities.
|
10.1*
|
1995
Stock Option Plan (Incorporated by reference to Exhibit F of our
Registration Statement on Form S-4 dated December 21, 1995, Commission
File No. 33-64031
|
10.2*
|
Amendment
to 1995 Stock Option Plan (Incorporated by reference to Exhibit 10.25
of
our Form 10-K for the year ended December 31,
2001)
|
10.3
|
Lease
Agreement between Pollock Realty Corporation and us dated July 25,
1996
(Incorporated by reference to Exhibit 10.19 of our Form 10-Q for
the
quarter ended September 30, 1996)
|
10.4
|
Platinate
HPMA Copolymer Royalty Agreement between The School of Pharmacy,
University of London and the Company dated November 19, 1996 (Incorporated
by reference to Exhibit 10.11 of our Form 10-K for the year ended
December
31, 1996)
|
10.5*
|
Employment
Agreement of David P. Nowotnik, PhD (Incorporated by reference to
Exhibit
10.19 of our Form 10-K for the year ended December 31,
1999)
|
10.6*
|
401(k)
Plan (Incorporated by reference to Exhibit 10.20 of our Form 10K
for the
year ended December 31, 1999)
|
10.7
|
Form
of Convertible Note (Incorporated by reference to Exhibit 10.24 of
our
Form 10-Q for the quarter ended September 30,
2000)
|
10.8
|
Rights
Agreement, dated as of October 31, 2001 between the us and American
Stock
Transfer & Trust Company, as Rights Agent (incorporated by reference
to Exhibit 99.1 of our Current Report on Form 8-K dated October 19,
2001)
|
10.9
|
Amendment
to Rights Agreement, dated as of February 16, 2006 between us and
American
Stock Transfer & Trust Company, as Rights Agent
(2)
|
10.10
|
Amendment
to Rights Agreement, dated as of November 9, 2007 between us and
American
Stock Transfer & Trust Company as Rights
Agent
|
10.11*
|
2001
Restricted Stock Plan (Incorporated by reference to Appendix A of
our
Proxy Statement filed on April 16,
2001)
|
10.12*
|
2005
Equity Incentive Plan (Incorporated by reference to Exhibit 1 of
our Proxy
Statement filed on April 18, 2005
(2)
|
10.13*
|
Employment
Agreement, dated as of June 1, 2005 by and between us and Stephen
B.
Thompson (1)
|
10.14
|
Asset
Sale Agreement, dated as of October 12, 2005, between us and Uluru,
Inc.
(1)
|
10.15
|
Amendment
to Asset Sale Agreement, dated as of December 8, 2006, between us
and
Uluru, Inc. (3)
|
10.16
|
License
Agreement, dated as of October 12, 2005, between us and Uluru, Inc.
(1)
|
10.17
|
Form
of Warrant, dated February 16, 2006, issued by us to certain Purchasers
(2)
|
10.18
|
Form
of Warrant, dated October 24, 2006, issued by us to certain Purchasers
(3)
|
10.19
|
Form
of Warrant, December 6, 2006, issued by us to certain Purchasers
(3)
|
10.20*
|
2007
Special Stock Option Plan and Agreement, dated January 4, 2007, by
and
between us and Stephen R. Seiler, President and Chief Executive Officer
(4)
|
10.21*
|
Employment
Agreement, dated January 4, 2007 by and between us and Stephen R.
Seiler,
President and Chief Executive Officer
(4)
|
10.22
|
Note
Purchase Agreement dated April 26, 2007 between us and Somanta
Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 10.42
of our
Form 10-Q for the quarter ended June 30 30,
2007)
|
10.23
|
Preferred
Stock and Warrant Purchase Agreement, dated November 7, 2007, between
us
and certain Purchasers
|
10.24
|
Investor
Rights Agreement, dated November 10, 2007, between us and certain
Purchasers
|
10.25
|
Form
of Warrant Agreement dated November 10, 2007, between us and certain
Purchasers
|
10.26
|
Board
Designation Agreement, dated November 15, 2007, between us and SCO
Capital
Partners LLC
|
10.27
|
Amendment
and Restated Purchase Agreement, dated February 4, 2008 between us
and
certain Purchasers
|
10.28
|
Amended
and Restated Investor Rights Agreement, dated February 4, 2008 between
us
and certain Purchasers
|
10.29
|
Employment
Agreement, dated January 4, 2008 between us and Jeffrey B.
Davis
|
23.1
|
Consent
of Whitley Penn LLP
|
23.2
|
Consent
of Stonefield Josephson, Inc.
|
23.3
|
Opinion
of Bingham McCutchen LLP regarding the legality of the securities
to be
filed with amendment to this Registration
Statement
|
Exhib
|
*
|
[Management
contract or compensatory plan required to be filed as an Exhibit
to this
Form pursuant to Item 15(c) of the
report.]
|
**
|
To
be filed with Amendment to this Registration
Statement
|
(1)
|
Incorporated
by reference to our Form 10-K for the year ended December 31,
2005.
|
(2)
|
Incorporated
by reference to our Form 10-Q for the quarter ended March 31,
2006.
|
(3)
|
Incorporated
by reference to our Form 10-K for the year ended December 31,
2006.
|
(4)
|
Incorporated
by reference to our Form 10-Q for the quarter ended March 31,
2007.
|
|
Exhibit
|
Number
|
Description
of
Document
|
2.1
|
Amended
and Restated Agreement of Merger and Plan of Reorganization between
Access
Pharmaceuticals, Inc. and Chemex Pharmaceuticals, Inc., dated as
of
October 31, 1995 (Incorporated by reference to Exhibit A of the our
Registration Statement on Form S-4 dated December 21, 1995, Commission
File No. 33-64031)
|
2.2
|
Agreement
and Plan of Merger, by and among Access Pharmaceuticals, Inc., Somanta
Acquisition Corporation, Somanta Pharmaceuticals, Inc. Somanta
Incorporated and Somanta Limited, dated April 18, 2007. (Incorporated
by
reference to Exhibit 2.1 to our Form 8-K dated April 18,
2007)
|
3.0
|
Articles
of incorporation and bylaws
|
3.1
|
Certificate
of Incorporation (Incorporated by Reference to Exhibit 3(a) of our
Form
8-B dated July 12, 1989, Commission File Number
9-9134)
|
3.3
|
Certificate
of Merger filed January 25, 1996. (Incorporated by reference to Exhibit
E
of our Registration Statement on Form S-4 dated December 21, 1995,
Commission File No. 33-64031)
|
3.4
|
Certificate
of Amendment of Certificate of Incorporation filed January 25, 1996.
(Incorporated by reference to Exhibit E of our Registration Statement
on
Form S-4 dated December 21, 1995, Commission File No.
33-64031)
|
3.5
|
Certificate
of Amendment of Certificate of Incorporation filed July 18, 1996.
(Incorporated by reference to Exhibit 3.8 of our Form 10-K for the
year
ended December 31, 1996)
|
3.6
|
Certificate
of Amendment of Certificate of Incorporation filed June 18, 1998.
(Incorporated by reference to Exhibit 3.8 of our Form 10-Q for the
quarter
ended June 30, 1998
|
3.7
|
Certificate
of Amendment of Certificate of Incorporation filed July 31, 2000.
(Incorporated by reference to Exhibit 3.8 of our Form 10-Q for the
quarter
ended March 31, 2001)
|
3.8
|
Certificate
of Designations of Series A Junior Participating Preferred Stock
filed
November 7, 2001 (Incorporated by reference to Exhibit 4.1.h of our
Registration Statement on Form S-8, dated December 14, 2001, Commission
File No. 333-75136)
|
3.9
|
Amended
and Restated Bylaws (Incorporated by reference to Exhibit 3.1 of
our Form
10-Q for the quarter ended June 30,
1996)
|
3.10
|
Certificate
of Designation of Series A Cumulative Convertible Preferred Stock
filed
November 9, 2007
|
5.1**
|
Opinion
of Bingham McCutchen LLP regarding the legality of the
securities.
|
10.1*
|
1995
Stock Option Plan (Incorporated by reference to Exhibit F of our
Registration Statement on Form S-4 dated December 21, 1995, Commission
File No. 33-64031
|
10.2*
|
Amendment
to 1995 Stock Option Plan (Incorporated by reference to Exhibit 10.25
of
our Form 10-K for the year ended December 31,
2001)
|
10.3
|
Lease
Agreement between Pollock Realty Corporation and us dated July 25,
1996
(Incorporated by reference to Exhibit 10.19 of our Form 10-Q for
the
quarter ended September 30, 1996)
|
10.4
|
Platinate
HPMA Copolymer Royalty Agreement between The School of Pharmacy,
University of London and the Company dated November 19, 1996 (Incorporated
by reference to Exhibit 10.11 of our Form 10-K for the year ended
December
31, 1996)
|
10.5*
|
Employment
Agreement of David P. Nowotnik, PhD (Incorporated by reference to
Exhibit
10.19 of our Form 10-K for the year ended December 31,
1999)
|
10.6*
|
401(k)
Plan (Incorporated by reference to Exhibit 10.20 of our Form 10K
for the
year ended December 31, 1999)
|
10.7
|
Form
of Convertible Note (Incorporated by reference to Exhibit 10.24 of
our
Form 10-Q for the quarter ended September 30,
2000)
|
10.8
|
Rights
Agreement, dated as of October 31, 2001 between the us and American
Stock
Transfer & Trust Company, as Rights Agent (incorporated by reference
to Exhibit 99.1 of our Current Report on Form 8-K dated October 19,
2001)
|
10.9
|
Amendment
to Rights Agreement, dated as of February 16, 2006 between us and
American
Stock Transfer & Trust Company, as Rights Agent
(2)
|
10.10
|
Amendment
to Rights Agreement, dated as of November 9, 2007 between us and
American
Stock Transfer & Trust Company as Rights
Agent
|
10.11*
|
2001
Restricted Stock Plan (Incorporated by reference to Appendix A of
our
Proxy Statement filed on April 16,
2001)
|
10.12*
|
2005
Equity Incentive Plan (Incorporated by reference to Exhibit 1 of
our Proxy
Statement filed on April 18, 2005
(2)
|
10.13*
|
Employment
Agreement, dated as of June 1, 2005 by and between us and Stephen
B.
Thompson (1)
|
10.15
|
Amendment
to Asset Sale Agreement, dated as of December 8, 2006, between us
and
Uluru, Inc. (3)
|
10.17
|
Form
of Warrant, dated February 16, 2006, issued by us to certain Purchasers
(2)
|
10.18
|
Form
of Warrant, dated October 24, 2006, issued by us to certain Purchasers
(3)
|
10.19
|
Form
of Warrant, December 6, 2006, issued by us to certain Purchasers
(3)
|
10.20*
|
2007
Special Stock Option Plan and Agreement, dated January 4, 2007, by
and
between us and Stephen R. Seiler, President and Chief Executive Officer
(4)
|
10.21*
|
Employment
Agreement, dated January 4, 2007 by and between us and Stephen R.
Seiler,
President and Chief Executive Officer
(4)
|
10.22
|
Note
Purchase Agreement dated April 26, 2007 between us and Somanta
Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 10.42
of our
Form 10-Q for the quarter ended June 30 30,
2007)
|
10.23
|
Preferred
Stock and Warrant Purchase Agreement, dated November 7, 2007, between
us
and certain Purchasers
|
10.24
|
Investor
Rights Agreement, dated November 10, 2007, between us and certain
Purchasers
|
10.25
|
Form
of Warrant Agreement dated November 10, 2007, between us and certain
Purchasers
|
10.26
|
Board
Designation Agreement, dated November 15, 2007, between us and SCO
Capital
Partners LLC
|
10.27
|
Amendment
and Restated Purchase Agreement, dated February 4, 2008 between us
and
certain Purchasers
|
10.28
|
Amended
and Restated Investor Rights Agreement, dated February 4, 2008 between
us
and certain Purchasers
|
10.29
|
Employment
Agreement, dated January 4, 2008 between us and Jeffrey B.
Davis
|
Exhib
|
*
|
[Management
contract or compensatory plan required to be filed as an Exhibit
to this
Form pursuant to Item 15(c) of the
report.]
|
**
|
To
be filed with Amendment to this Registration
Statement
|
(2)
|
Incorporated
by reference to our Form 10-Q for the quarter ended March 31,
2006.
|
(3)
|
Incorporated
by reference to our Form 10-K for the year ended December 31,
2006.
|
(4)
|
Incorporated
by reference to our Form 10-Q for the quarter ended March 31,
2007.
|